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ABSTRACT
Modulation of Coronary Reactive Hyperemia through Soluble Epoxide
Hydrolase: Role of Oxylipins and PPARγ
Ahmad Mahmoud Hanif

Ischemic heart disease (IHD) continues to be a leading cause of morbidity and mortality in
increasingly more countries. Function and structural damage to the heart are likely consequences
of ischemic insults and may even lead to death. The body’s physiological response to ischemia is
by increasing nourishment or perfusion to the deprived organ in an attempt to decrease the
potential ischemia-induced damage and achieve faster recovery. This reaction to ischemia is
termed reactive hyperemia (RH), and in the heart, it is coronary reactive hyperemia (CRH).
Epoxyeicosatrienoic acids (EETs) are oxylipins derived from arachidonic acid (AA) and possess
distinct cardiovascular benefits, such as vasodilation, cardio-protection in ischemia/reperfusion,
and anti-inflammation. Other oxylipins, such as HETEs, epoxyoctadecaenoic acid (EpOMEs),
HODEs, and prostanoids have versatile and yet incompletely elucidated cardiovascular effects.
Moreover, these oxylipins seem to be interconnected and can affect each other. For example, the
enzyme soluble epoxide hydrolase (sEH) is involved in the main catabolic pathway of EETs,
which are converted into dihydroxyeicosatrienoic acids (DHETs), and EpOMEs which are
converted into dihydroxyoctadecaenoic acids (DiHOMEs). The relationship among sEH, CYPepoxygenase pathway, oxylipins, PPAR, and CRH response to a brief ischemia is not known.
We hypothesized that targeting sEH, by pharmacologic inhibition or genetic deletion, enhances
CRH in isolated mouse hearts through changing the oxylipin profiles, including an increase in
EETs/DHETs ratio. Targeting sEH resulted in significant enhancement of CRH, including
repayment volume, repayment duration, and repayment/debt ratio (p ≤ 0.05). Also, oxylipin
profiles were changed because of sEH targeting, including increase in EET/DHET ratio, increase
in EpOME/DiHOME ratio, increase in the level of HODEs, decrease in the levels of mid-chain
HETEs, and decrease in prostanoids (p ≤ 0.05). Involvement of PPAR in the modulation of
CRH was demonstrated using a PPAR-antagonist (T0070907) and a PPAR-agonist
(rosiglitazone). T0070907 reduced CRH (p ≤ 0.05), whereas, rosiglitazone enhanced CRH (p ≤
0.05) in isolated mouse hearts compared to the non-treated.
These data demonstrate that sEH disruption enhances CRH possibly through causing changes in
oxylipin profiles. Also, PPARγ mediate CRH downstream of the CYP epoxygenases-EET
pathway.
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INTRODUCTION

Reactive Hyperemia
When the heart is subjected to a brief period of ischemia it responds by momentarily increasing
coronary blood flow (12), which is known as reactive hyperemia (RH) or Coronary RH (CRH).
The phenomenon of CRH is associated with significant coronary vasodilation in response to
cessation in coronary perfusion. This phenomenon is not unique to the heart; it is observed in
other tissues when they are temporarily deprived of blood perfusion. This occlusion, or ischemia,
is inherently associated with potentially detrimental effects on the heart and cardiac function.
The increase in blood flow coupled with CRH is known as repayment volume; it aims at
preventing or lessening the potential injury due to ischemia. It helps do so by speeding up
functional recovery through supplying more-than usual blood to nourish the deprived heart
muscle and wash away accumulated metabolic byproducts (105). Therefore, CRH, as is reactive
hyperemia elsewhere in the body, may be viewed as a protective mechanism against ischemia.
Research has shown that CRH is attenuated in pathologic conditions affecting blood vessels
including the coronary blood vessels. Previous research has also confirmed that CRH is
decreased in cardiac hypertrophy (36) and metabolic syndrome (6). Moreover, higher risk of
cardiovascular conditions, such as unstable angina, myocardial infarction, congestive heart
failure and cardiac death, are linked to decreased CRH (30). Additionally, corrective measures
have been shown to reverse or mitigate this association. Patients with acute myocardial
infarction, who had blunted CRH, had significant improvement in CRH after successful coronary
angioplasty as measured by coronary angiography (91). Another useful application of CRH is
that it serves as a measure of coronary vascular reserve (CVR), which is traditionally measured
1

using pharmacological agents. However, CRH is an accepted alternative for estimating CVR
(38). A number of parameters can be evaluated during CRH; figure I illustrates these
parameters. Additionally, heart rate (HR) and left ventricular developed pressure (LVDP) are
used to evaluate the basic function of the heart in response to CRH and the drugs used to study it.
Extensive work has been done to study the mechanisms and mediators involved in reactive
hyperemia. These mechanisms may be broadly divided into two categories, mechano-senstive
and metabolic (105). The mechano-senstive mechanisms include shear stress and myogenic
response. On the other hand, the list of metabolic mediators include adenosine, which plays an
important role through acting on its receptor subtypes A2A and A2B (5, 36), nitric oxide (NO)
(36), ATP-dependent K+ (KATP) channels, which function downstream of adenosine (36, 80), and
hydrogen peroxide (H2O2), which functions downstream of adenosine (36, 80). H2O2 is one of
the endothelium-derived hyperpolarizing factors (EDHFs). Likewise, Campbell et al. identified
epoxyeicosatrienoic acids (EETs) as EDHF (9).
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Figure I: Different parameters derived from coronary reactive hyperemia before and after 15-sec
no-flow ischemia

3

Oxylipins
Oxylipins are bioactive lipids generated by the oxidation of polyunsaturated fatty acids (PUFAs)
(95). Since their discovery almost five decades ago, numerous biologic functions have been
linked to them, and many others are still being elucidated. The advancement in detection and
quantification rejuvenated both interest and research in oxylipins with accurate nanomolar
detection using an array state-of-the-art mass spectrometry instruments (89). Still, studying the
biologic functions of oxylipins is challenged by the sheer number of oxylipins discovered thus
far, over 100 oxylipins have been discovered (95), and the overlapping and interconnected roles
different oxylipin groups have. Important cardiovascular disease (CVD) pathologies, including
hyperlipidemia, hypertension, thrombosis, hemostasis, and diabetes have been linked to
abnormal oxylipin signaling (25).
Oxylipins derived from arachidonic acid (AA) include EETs, HETEs, and prostanoids, whereas
those derived from linoleic acid (LA) include EpOMEs and HODEs among others. Figure II
illustrates some of AA- and LA-derived oxylipins and the main enzymes involved in their
generation and breakdown, such as CYP epoxygenases and sEH.

Biosynthesis:
Oxylipins are both potent and short lived. Therefore, they are not stored; they are rather
synthesized de novo and regulated closely, and exert their effect in a paracrine or autocrine
manner (95). Free PUFAs are mono- or dioxygenated by three families of enzymes:
cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) into distinct classes
of oxylipins (50). The type of oxylipins produced from PUFAs depends on the amount of dietary
PUFAs consumed, the oxygenases (COX, LOX or CYP) present for metabolizing PUFAs, and
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the enzyme’s affinity for a specific substrate PUFA (22). The most well-known oxylipins are the
eicosanoids (20-carbon compounds) formed from arachidonic acid (AA), and octadecanoids (18carbon compounds) derived from linoleic acid (LA) (22). Cyclooxygenase (COX) enzymes
convert AA into prostanoids (PGs and thromboxanes). Also, COX enzymes can produce some
hydroxy-metabolites, such as 11-HETE from AA, and 9-HODE from LA (94). Lipoxygenases
(LOXs) catalyze the formation of hydroxy fatty acids, including leukotrienes, lipoxins, resolvins,
protectins, maresins, hepoxilins, and eoxins (22). LOX enzymes also metabolize AA to form
mid-chain (5-, 8-, 9-, 11-, 12-, and 15-) HETEs (3). Cytochrome P450 (CYP) enzymes, which
were originally known for their roles in xenobiotic metabolism, could either have epoxygenase
or -hydroxylase activity (22). CYP -hydroxylase enzymes (CYP4A and CYP4F) metabolize
AA and generate -terminal (16-, 17-, 18-, 19-, and 20-) HETEs, whereas CYPs with
epoxygenase activity (CYP2C and CYP2J) metabolize AA and generate epoxyeicosatrienoic
acid (EETs), which are further metabolized to dihydroxyeicosatrienoic acids (DHETs) by soluble
epoxide hydrolase (sEH) (95). AA can also be generated from LA metabolism (40). Metabolism
of LA includes the same enzyme families described above; for example, CYP epoxygenases
metabolize LA to form EpOMEs, the epoxy compounds of LA. EpOMEs are hydrated by sEH to
form DiHOMEs, the dihydroxy form of EpOMEs (3). LOX enzymes form the hydroxy
metabolites of LA: HODEs (95). Oxylipins have a wide range of biological functions, many of
which are still being investigated. They produce their effects through activating PPARs, or
through GPCRs (81). Targeting sEH impacted the level of oxylipins directly affected by its
catalytic activity, such as EETs, DHETs, EpOMEs, and DiHOMEs, and indirectly by affecting
the other PUFAs pathways, such as HODEs, and HETEs (45, 47). The latter observation could
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be explained by the shift observed in sEH–/– in AA metabolism due to EETs accumulation (39),
suggesting that the different oxylipin pathways affect one another.

Epoxyeicosatrienoic acids (EETs)
EETs are 20-carbon metabolites of arachidonic acid (AA) with numerous physiologic actions.
They are generated from AA by the cytochrome P450 epoxygenase pathway. Four distinct
regioisomers are produced: 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET. In the heart, EETs
exert cardioprotective effects in ischemia / reperfusion injury (77). EETs are classified as
EDHFs; they are produced in endothelial cells and induce hyperpolarization in vascular smooth
muscle cells by activating large conductance Ca2+-activated K+ channels (BKCa) (9, 20). EETs
also cause vasodilation in many vascular beds such as the intestines (71), kidney preglomerular
vasculature (33), conduit arteries (57-61), and brain (23). It is worth mentioning that small
(KCa2.3) and medium (KCa3.1) conductance Ca2+-activated K+ channels are important in EETsinduced hyperpolarization (20). EETs are metabolized rapidly by hydration to their
corresponding, less active, dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase
sEH, which is the main catabolic pathway responsible for EETs breakdown (83). Not all EETs
isomers are substrates for sEH; 5,6-EET is a poor substrate of sEH. In fact, this EET isomer
along with 8,9-EET are substrates for cyclooxygenase (COX) pathway (32). The terminal halflife of 14,15-EET was found to be between 7.9 – 12.3 minutes (10). Other catabolic pathways of
EETs include -oxidation, -oxidation, and chain elongation. The latter two pathways become
more important when the activity of the main pathway, hydration by sEH, is inhibited (32). Not
only were EETs shown to have confirmed beneficial effects in numerous animal studies through
their vasodilatory (23, 33, 57-61, 71), cardioprotective (77), and anti-inflammatory effects (79),
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they were also linked to decreased cardiovascular risk in epidemiological studies in humans (42,
43). Polymorphism variants where EETs production is decreased, such as decreased CYP2J2
expression (variant G-50T) (42) or EETs breakdown is increased, such as increased sEH activity
(variant K55R) (43), had increased risk of coronary artery disease. It was speculated by some
researchers that EETs exert their effects through specific cell surface receptors, which is
supported by the finding that different responses were elicited by different stereoisomers and
regioisomers of EETs (100). However, it is worth mentioning that numerous reports linked
EETs’ signaling pathway with protein kinase A (PKA) and cAMP (63).
Mid-chain Hydroxyeicosatetraenoic Acids (HETEs):
Mid-chain HETEs are produced through allylic oxidation of AA by lipoxygenase (LOX) (39).
They were shown to have chemotaxis effects, change vascular tone, and induce the production of
vascular endothelial growth factors (29, 56, 86, 93). Also, the increased formation of mid-chain
HETEs was involved in cardiovascular dysfunction (13, 68, 87, 97). Unlike the vasodilatory
effect of EETs in the kidneys (33), 12-HETE caused vasoconstriction in small renal arteries (48).
Also, the generation of mid-chain HETEs is increased in essential hypertension (16) suggesting
that they could be involved in its pathogenesis. These reports point to opposite effects of EETs
and HETEs in vascular biology. Maayah et al. reported that mid-chain HETEs blocked the
synthesis of EETs and increased their conversion to DHETs in RL-14 cells (49). Moreover,
although sEH is not directly involved in the generation or breakdown of mid-chain HETEs, sEH
was found to be essential for mid-chain HETE–mediated induction of cellular hypertrophy (49).
Therefore, not only do EETs and mid-chain HETEs have opposite effects, they seem to affect the
level of each other.
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Epoxyoctadecaenoic acid (EpOMEs):
The physiological significance of EpOMEs and DiHOMEs remains poorly understood, and the
evidence is somewhat contradictory, with a few studies suggesting toxic effects, while others
indicating beneficial effects of these bioactive metabolites. EpOMEs and DiHOMEs were
reported to increase oxidative stress in vascular endothelial cells (96); DiHOMEs were toxic to
renal proximal tubular cells (54); and intravenously injected 9,10-EpOME had cardiodepressive
effects in dogs (90). The main caveat of these studies, which reported that EpOMEs and
DiHOMEs have toxic effects, is that very high concentrations (100 – 500 M) were used (39).
Contrary to these reports, lower, more physiological concentrations of EpOMEs and DiHOMEs
did not have toxic effects and rather had beneficial effects (52). Mitchell et al reported that LA
and its oxidative metabolites (EpOMEs and DiHOMEs) did not have toxic effects during acute
exposure in Langendorff-perfused rat hearts (52). Pretreatment with 12,13-EpOME protected
primary cultures of rabbit renal proximal tubular cells against hypoxia/reoxygenation injury (65).
Also, increased EpOME/DiHOME ratio, induced by sEH inhibition using AUDA, improved
renal recovery in response to ischemia/reperfusion injury in C57BL/6 mice (44).

Hydroxyoctadecadienoic Acids (HODEs):
Linoleic acid (LA) is also metabolized through hydroxylation by CYP epoxygenases to form
hydroxyl-LA metabolites known as hydroxyoctadecadienoic acids (HODEs) (39). Like EpOMEs,
the physiologic functions of HODEs are still being investigated (39). 13-HODE is suggested to
have an anti-inflammatory role in inflammatory diseases through its effect as a PPARγ-agonist
(2, 4, 18, 21, 88). Also, 13-HODE, through increasing prostacyclin (PGI2) biosynthesis, was
involved in splenic and coronary artery relaxation in smooth muscle cells in Mongrel dogs (15).
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9-HODE, unlike 13-HODE, was described as pro-inflammatory in an experimental woundhealing model in rats (26, 66).

Prostanoids:
The term prostanoids comprises two distinct groups: prostaglandins and thromboxanes.
Prostaglandins G2 and H2, which are AA metabolites formed by COX isoforms (1 and 2), are
converted to the 4 main bioactive PGs (D2, E2, I2, and F2) and thromboxanes (TxA2 and TxB2)
(74, 92). Most PGs have pro-inflammatory effects. For example, PG-E2 augments arterial dilation
and increases microvascular permeability (92). However, PG-E2 was found to have an antiinflammatory role as well by up-regulating cAMP and inducing secretion of the antiinflammatory IL-10 (78). Similarly, PG-D2 attenuated inflammation in experimental models of
pleuritis and colitis (92). 6-keto-PG-F1, the non-active hydrolysis product of prostacyclin (PGI2), and TxB2, the inactive degradation product of TxA2 (92), were also decreased by t-AUCB.
Targeting sEH was shown to affect the level of different PGs. For example, sEH-inhibition by
AUDA-BE reversed lipopolysaccharide (LPS)-induced increase in PG-D2, PG-E2, 6-keto-PG-F1,
and TxB2 (76). Also, sEH-inhibition by AUDA-BE, through increasing the concentrations of
EETs, inhibited NF-B translocation (75). Combination of sEH-inhibition by AUDA-BE and
COX-inhibition had an additive effect and further decreased PG-D2 and PG-E2 (75).
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catabolism. (Tam et al., 2013)
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Coronary Reactive Hyperemia in the Isolated Perfused Heart
The Langendorff perfused heart technique is well established. It has evolved substantially since it
was first conceived for mammalian hearts by Oscar Langendorff in 1897 (84). Of the two
available types of this technique, we chose the constant pressure mode to prefuse the heart over
the constant flow mode. In the latter mode, the amount of perfusate is not physiologically
modulated in response to the changing needs of the heart muscle as a result of overriding the
autoregulatory mechanisms by providing constant flow of the perfusate. This is especially
important when trying to assess the role of coronary regulatory mechanisms in response to
changing coronary flow conditions or pathologies such as ischemia. Based on that, the constant
pressure mode is physiologically more relevant in experiments involving ischemia (84). Figure
III illustrates a schematic picture showing the setup of Langendorff perfused heart experiment.
Although the Langendorff perfused heart technique has been criticized for a number of
limitations, its overall advantages and reproducibility still make it a valuable tool for studying
both physiologic and pathologic changes in the heart, particularly when cardiac ischemia or
hypoxia are being investigated. Some of the reported disadvantages include a requirement of
certain level of skill in handling the heart and preparing it for experiments. This is particularly
noticed when dealing with small animals such as mice; it is rather a demanding technique and
takes some time to develop the skill for it. Another related point, which is critical for the
integrity of the heart, is the time the heart spends under ischemic state; it is absolutely vital to
instantly place the excised heart in ice-cold buffer to slow the metabolism and therefore diminish
the oxygen requirements of the heart. Removing the surrounding tissues, such as lungs, trachea
and blood vessels, and preparing the aorta for hanging should be quick and done while the heart
is immersed in the ice-cold buffer. Once hanged and fixed in place, the already warmed and
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oxygenated buffer should be allowed to perfuse the heart. Besides taking all the above mentioned
precautions into consideration, we perform an extra final step to make sure that the heart
endothelium is still intact and the heart is still suitable for experimentation. This step is the
induction of reactive hyperemia in response to a 15 sec ischemia, which happens to be the main
variable in our study. This has been the golden standard to ascertain the integrity of the heart. We
only proceed with our experiment if the maximum coronary flow in response to the 15 sec
ischemia is increased by at least 2 or more fold.
Also, in Langendorff technique, the fact that the heart is disconnected from the body and the
extrinsic control of the humoral and nervous systems could be viewed as a disadvantage.
Actually, this may be considered an advantage as it allows the evaluation of drug effects on the
heart while excluding any extrinsic effect, which could modulate its response. Another reason for
using the Langendorff perfused heart technique is that the epoxygenase pathway is not functional
in cell culture systems (32).
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Peroxisome Proliferator-Activated Receptors (PPARs)
PPARs are nuclear receptors, which, upon activation, modulate DNA transcription of target
genes (98). Three subtypes of PPARs are identified:  and  (51). Because of their large
ligand-binding domain, PPARs can bind to a large number of ligands (64, 99). PPARs are
involved in many biologic functions, such as vascular tone regulation, inflammation, energy
homeostasis, adipogenesis, and insulin sensitivity (11, 31, 64, 99). Many of EETs’ effects have
been linked to PPAR (59, 70). The anti-inflammatory effect of EETs in cultured endothelial
cells was induced by laminar flow and mediated by PPAR (46). Cowart et al reported that EETs
metabolites formed by Cyp4a were high-affinity ligands of PPAR(14). Also, Cai et al reported
that EETs protected against Angiotensin II – induced abdominal aortic aneurysm in cyp2j2overexpressed mice through PPAR (8). These (8, 14, 46, 59, 70) and other reports prompted us
to investigate a possible link among CYP-epoxygenases, sEH, oxylipins and PPAR in
modulating CRH response.
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Hypothesis and Project Summary:
Coronary reactive hyperemia (CRH) is a physiological response to ischemic insult that prevents
the potential harm associated with ischemia or interruption of blood supply. The relationship
between the pharmacologic inhibition or genetic deletion of soluble epoxide hydrolase (sEH) and
CRH response to a brief ischemia is not known. EETs protect against ischemia/reperfusion injury
and have numerous beneficial physiological effects. sEH is involved in the main catabolic
pathway of epoxyeicosatrienoic acids (EETs), which are converted into dihydroxyeicosatrienoic
acids (DHETs). Oxylipins are inter-connected through sharing common precursor molecules and
through affecting each others’ levels. The potential role of targeting sEH in coronary flow (CF)
during CRH in response to short ischemia has not been investigated. Therefore, we hypothesized
that targeting sEH, through pharmacologic inhibition or genetic deletion, enhances CRH in
isolated mouse hearts through changing the oxylipin profiles.
To test this hypothesis, we had the following specific aims:


Specific Aim 1:
Investigate the effect of sEH deletion on CRH and oxylipins using gene manipulated
sEH-knockout (sEH–/–) and wild type (sEH+/+) mice.



Specific Aim 2:
Investigate the effect of sEH inhibition on CRH and oxylipins using pharmacology in
wild type (sEH+/+) mice.



Specific Aim 3:
Explore the role of PPAR in the downstream signaling pathway involved in CRH
through disruption of sEH using gene manipulated technology and pharmacology.
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CHAPTER ONE

Deletion of Soluble Epoxide Hydrolase Enhances Coronary Reactive Hyperemia in Isolated
Mouse Heart: Role of Oxylipins and PPAR
(This chapter was published in the American Journal of Physiology-Regulatory, Integrative and
Comparative Physiology)
(2016 Oct 1;311(4):R676-R688. doi: 10.1152/ajpregu.00237.2016. Epub 2016 Aug 3.)
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Abstract:
The relationship between soluble epoxide hydrolase (sEH) and coronary reactive hyperemia
(CRH) response to a brief ischemic insult is not known. Epoxyeicosatrienoic acids (EETs) exert
cardioprotective

effects

in

ischemia/reperfusion

injury.

sEH

converts

EETs

into

dihydroxyeicosatrienoic-acids (DHETs). Therefore, we hypothesized that knocking out sEH
enhances CRH through modulation of oxylipin profiles including an increase in EETs/DHETs
ratio. Compared to sEH+/+, sEH–/– mice showed enhanced CRH, including greater repayment
volume (RV; 28% higher, p<0.001) and repayment/debt ratio (32% higher, p<0.001). Oxylipins
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from the heart perfusates were analyzed by LC-MS/MS. The 14,15-EET/14,15-DHET ratio was
3.7 fold higher at baseline (p<0.001) and 5.6 fold higher post-ischemia (p<0.001) in sEH–/–
compared to sEH+/+ mice. Likewise, the baseline 9,10- and 12,13-EpOME/DiHOME ratios were
3.2 (p<0.01) and 3.7 (p<0.001) fold higher, respectively in sEH–/– compared to sEH+/+ mice. 13HODE was also significantly increased at baseline by 71% (p<0.01) in sEH–/– vs. sEH+/+ mice.
Levels of 5-, 11-, 12-, and 15-HETEs were not significantly different between the two strains
(p>0.05), but were decreased post-ischemia in both groups (p=0.02, p=0.04, p=0.05, p=0.03
respectively). Modulation of CRH by PPAR was demonstrated using a PPAR-antagonist
(T0070907), which reduced repayment volume by 25% in sEH+/+ (p<0.001) and 33% in sEH–/–
mice (p<0.01), and a PPAR-agonist (rosiglitazone), which increased repayment volume by 37%
in both sEH+/+ (p=0.04) and sEH–/– mice (p=0.04). L-NAME attenuated CRH in both sEH–/– and
sEH+/+. These data demonstrate that genetic deletion of sEH resulted in an altered oxylipin
profile which may have led to an enhanced CRH response.

Introduction
During reactive hyperemia (RH), blood flow increases transiently in response to ischemia or
interruption of blood supply (105). In the heart, RH is referred to as coronary RH (CRH), and is
associated with coronary vasodilation in response to cessation in coronary perfusion. This
occlusion or ischemic insult is inherently associated with potentially detrimental effects on the
heart and cardiac function. The increase in blood flow associated with CRH increases repayment
volume (RV) to prevent or decrease potential injury due to ischemia. CRH speeds up functional
recovery by supplying more than the usual amount of blood to nourish the deprived heart muscle,
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and wash away accumulated metabolic byproducts (105); therefore, CRH may be viewed as a
protective mechanism. Research has shown that RH is blunted in pathologic conditions affecting
blood flow including the coronary circulation; CRH is decreased in cardiac hypertrophy (36) and
metabolic syndrome (6). Moreover, higher risk for cardiovascular diseases, such as unstable
angina, myocardial infarction, congestive heart failure, and cardiac death are linked to decreased
CRH (30). Corrective measures, such as coronary angioplasty, have been shown to reverse or
mitigate decreased CRH in patients with acute myocardial infarction, and significantly improved
CRH after successful coronary angioplasty (91). Although coronary vascular reserve is
traditionally measured through pharmacological agents, CRH is also an accepted alternative to
measure it if patients cannot tolerate the pharmacological agents (38).
The mechanisms and mediators involved in RH have been studied extensively. These
mechanisms may be broadly divided into two categories: mechanosensitive and metabolic (105).
The mechanosensitive mechanisms include shear stress and myogenic response. Metabolic
mediators involved in RH include adenosine (5, 36), nitric oxide (NO) (36), KATP channels (36)
and hydrogen peroxide (H2O2) (36, 80).
Epoxyeicosatrienoic acids (EETs) are oxidized metabolites of arachidonic acid (AA) that have
numerous physiologic actions. EETs are produced in endothelial cells and induce
hyperpolarization and relaxation in vascular smooth muscle cells by activating large conductance
Ca2+-activated K+ channels (BKCa) (9, 20). EETs are rapidly metabolized by soluble epoxide
hydrolase (sEH) to less active dihydroxyeicosatrienoic acids (DHETs) through hydration, the
main catabolic pathway responsible for EETs breakdown (83); therefore, targeting sEH is
associated with beneficial effects on the cardiovascular system (19, 59). Also, others (17, 39, 45)
have reported that sEH–/– mice were associated with elevated EETs levels compared to sEH+/+
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mice, and EETs exerted cardioprotective effects against ischemia/reperfusion injury (77).
Additionally, targeting sEH impacted the level of oxylipins, such as EpOMEs, DiHOMEs,
HODEs, and HETEs (45, 47). Lee et al., (44) reported that EpOMEs/DiHOMEs ratio was
increased in response to the sEH inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid
(AUDA) in vivo; this change was associated with improved renal recovery against ischemia
reperfusion injury in C57BL/6 mice. Guido et al., (15) reported that 13-HODE
(hydroxyoctadecadienoic acids) was involved in canine splenic and coronary artery relaxation
through PGI2 (prostacyclin) biosynthesis in both endothelial and smooth muscle cells. Mid-chain
HETEs (hydroxyeicosatetraenoic acids) had direct chemo-toxic effects on vascular tone and
production of endothelial vascular factors, such as vascular endothelial growth factor (VEGF),
and pigment epithelium-derived factor (PEDF) (1, 29, 56, 86, 93). Further, EETs-induced aortic
relaxation in mice was mediated by peroxisome proliferator-activated receptor gamma (PPAR)
(59, 70). Also, in mouse mesenteric arteries, EETs-induced vasodilatory effects were inhibited
by L-NAME (a non-selective NO synthase, NOS, inhibitor) (28). Seubert et al., (77) reported
that CYP2J2 over-expression in the mouse heart involved increased generation of EETs
compared

to

their

respective

control

and

exerted

cardioprotective

effects

against

ischemia/reperfusion injury. However, the potential role of sEH deletion in coronary flow (CF)
during CRH in response to short ischemia has not been investigated. Therefore, we hypothesized
that knocking out sEH enhances CRH in isolated mouse heart through modulation of oxylipin
profiles including an increase in EETs/DHETs ratio.

Materials and Methods
Animals
19

The generation of sEH–/– mice was described by Sinal et al. (83). sEH–/– and sEH+/+ mice were
provided by Dr. Darryl Zeldin, National Institute of Environmental Health Sciences / National
Institutes of Health (NIH). All animal care and experimentation protocols were approved and
carried out in accordance with the West Virginia University Institutional Animal Care and Use
Committee and were in accordance with the principles and guidelines of the NIH’s Guide for the
Care and Use of Laboratory Animals. Both male and female mice (14 –16 wks old) in equal
ratio were used in our study. Mice were maintained in cages with a 12:12 h light-dark cycle and
free access to standard chow and water.

Langendorff-Perfused Heart Preparation
The Langendorff perfused heart preparation is a well-established technique for studying the
cardiac functions and pathologies in vitro. There are two available Langendorff technique modes
to perfuse the heart: 1) constant pressure mode, and 2) constant flow mode. In our experiments,
we chose the constant pressure mode. The selection between the two is especially important
when trying to assess the role of coronary regulatory mechanisms in response to changing CF
conditions or pathologies such as ischemia. Based on that, the constant pressure mode is
physiologically more relevant in experiments involving ischemia, like the model in our
experiments (84).

Deletion of sEH in sEH–/– mice was confirmed by genotyping of mouse tail samples (data not
shown). Also, Western blotting confirmed the deletion of sEH protein in sEH–/– mice aortic
samples and was reported by our laboratory (59). Soluble epoxide hydrolase null (sEH–/–) and
wild-type mice (sEH+/+) mice (14–16 wks.) of both sexes (equal ratios) were euthanized with
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sodium pentobarbital (100 mg/kg body weight intra-peritoneally). Hearts were excised and
immediately placed into heparinized (5 U/mL) ice-cold Krebs-Henseleit buffer containing (in
mM) 119.0 NaCl, 11.0 glucose, 22.0 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, 2.0
pyruvate, and 0.5 EDTA. After removal of the lung and surrounding tissue around the heart, the
aorta was rapidly cannulated with a 20-gauge, blunt-ended needle and continuously perfused
with 37°C buffer continuously bubbled with ([95% O2] – [5% CO2]) at a constant perfusion
pressure of 80 mmHg. The left atrium was excised, and a water-filled balloon made of plastic
wrap was inserted into the left ventricle through the mitral valve. The balloon was connected to a
pressure transducer for continuous measurement of left ventricular developed pressure (LVDP)
and heart rate (HR). The heart was then immersed in a water-jacketed perfusate bath (37o C) and
left to beat spontaneously. Left ventricular diastolic pressure was adjusted to 2–5 mmHg. A flow
transducer was installed above the cannulated aorta for continuous measurement of CF with an
ultrasonic flow probe (Transonic Systems, Ithaca, NY). A Power–Lab Chart data acquisition
system (AD Instruments, Colorado Springs, CO) was used for data acquisition. Heart was
allowed to stabilize for 30–40 min before initiation of CRH. Only hearts whose peak CF
increased by more than two fold after a 15-second total occlusion were included in the analysis.
This demonstrated that the isolated heart preparation was intact to be included in the experiment.
Hearts with persistent arrhythmias or LVDP of less than 80 mmHg were excluded. 9 mice (4
males and 5 females), out of 58 mice, were excluded from our study for the mentioned reasons.

Coronary Reactive Hyperemic Response:
After stabilization for 30–40 minutes, baseline CF, HR, and LVDP were recorded. Hearts were
subjected to 15 seconds of total occlusion by closing the valve directly above the cannulated
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heart to bring forth CRH. After CF returned to pre-CRH baseline levels, post-CRH baseline CF,
CF tracing, peak hyperemic flow (PHF), HR, LVDP, repayment volume (RV), and repayment
duration (RD) recordings were analyzed for each isolated heart. Investigation drugs were infused
into the aortic perfusion line using a microinjection pump (Harvard Apparatus, Holliston, MA)
for 15 minutes, after which another CRH was induced and the same parameters analyzed again.
Drugs were infused at a rate equivalent to 1% of CF. The final concentrations, after
standardization of dose (0.01, 0.1, 1, & 10 M) response for the various drugs used in this study
were 10 M for T0070907 (PPAR-antagonist), rosiglitazone (PPARagonist), and 100 M for
L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride, a non-selective nitric oxide synthase
inhibitor). These concentrations were selected based on our dose-response studies (for T0070907
and rosiglitazone) and based on the concentrations used in previous studies (rosiglitazone, 10
M; (67)), and (L-NAME, 100 M; (105)). Time-matched control experiments with WT
(sEH+/+) mouse hearts, employing three consecutive inductions of CRH, showed no change in
CRH response and in baseline heart functions, including CF, LVDP, and HR (data not shown).

LC–MS/MS Oxylipin Analysis
Oxylipin levels (5,6-, 8,9-, 11,12- and 14,15-EETs; 5,6-, 8,9-, 11,12- and 14,15-DHETs; 5-, 8-,
9-, 11-, 12- and 15-HETEs; 9,10- and 12,13-EpOMEs; 9,10- and 12,13-DiHOME; 9- and 13HODEs) were analyzed in pre- and post CRH heart perfusates of sEH–/– and sEH+/+ mice
through liquid chromatography, tandem mass spectroscopy (LC–MS/MS) as described
previously (41). Briefly, heart perfusates were collected after the first 30 min of stabilization, and
right after reperfusion for 2.5 min. Hearts were immersed in 5 mL of warm (37°C) KrebsHenseleit buffer and 5 L of 10 M t-AUCB (trans-4-[4-(3-adamantan-1-yl-ureido)-
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cyclohexyloxy]-benzoic acid, selective sEH-inhibitor) to block further breakdown of EETs and
EpOMEs by sEH. Heart perfusates were collected two times before (at baseline) and pooled
together as one sample, and two times after ischemia and pooled together as another sample for
LC-MS/MS analysis. Samples were stored at –80°C until processing. Samples were spiked with
30 ng PGE2-d4, 10,11- DiHN, and 10,11-EpHep (Cayman) as internal standards, mixed with 0.1
vol of 1% acetic acid in 50% methanol, and extracted by serial passage through Oasis HLB C18
3mL columns (Waters, Milford, MA, USA). Columns were washed twice with 0.1% acetic acid
in 5% methanol, and eluted with methanol into glass tubes containing 6 L of 30% glycerol in
methanol. The methanol was then evaporated under a stream of nitrogen gas, and the dried tubes
were frozen and stored at –80°C until analysis. Online liquid chromatography of extracted
samples was performed with an Agilent 1200 Series capillary HPLC (Agilent Technologies,
Santa Clara, CA, USA). Separations were achieved using a Halo C18 column (2.7 mm, 10062.1
mm; MAC-MOD Analytical, Chadds Ford, PA), which was held at 50°C. Mobile phase A was
85:15:0.1 water: acetonitrile: acetic acid. Mobile phase B was 70:30:0.1 acetonitrile: methanol:
acetic acid. Flow rate was 400 L/min. Gradient elution was used. Mobile phase percentage B
and flow rates were varied as follows: 20% B at 0 min, ramp from 0 to 5 min to 40% B, ramp
from 5 to 7 min to 55% B, ramp from 7 to 13 min to 64% B. From 13 to 19 min the column was
flushed with 100% B at a flow rate of 550 L/min. Samples were solvated in 50 l of 30%
ethanol. The injection volume was 10 L. Samples were analyzed in triplicate. Analyses were
performed on an MDS Sciex API 3000 equipped with a TurboIonSpray source (Applied
Biosystems). Turbo desolvation gas was heated to 425°C at a flow rate of 6 L/min. Negative ion
electrospray ionization tandem mass spectrometry with multiple reaction monitoring was used
for detection.
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Effect of PPARγ-antagonist (T0070907) on CRH Response in sEH–/– and sEH+/+ Mice:
Isolated hearts from sEH–/– and sEH+/+ mice were stabilized for 30–40 min followed by 15 sec of
total occlusion. Recordings of the first CRH (baseline CF, CF tracing, LVDP, HR, RV, PHF and
RD) were analyzed for each heart and averaged for each group, as mentioned previously. The
PPARγ-antagonist, T0070907, was infused at a final concentration of 10 M and 1% of CF rate
for 15 min, after which, another CRH was induced and the same parameters were recorded and
analyzed.

Effect of PPAR-agonist (Rosiglitazone) on CRH in sEH–/– and sEH+/+ Mice:
After stabilization, hearts from sEH–/– and sEH+/+ mice were subjected to 15 sec of total
occlusion. As described above, baseline CRH was induced in each mouse heart. Then, the
PPARγ-agonist, rosiglitazone, was infused at a final concentration of 10 M for 15 min,
followed by another CRH. CRHs before and after rosiglitazone infusion were analyzed.

Effect of L-NAME on CRH Response in sEH–/– and sEH+/+ Mice:
Baseline CRH was induced in each mouse strain. The non-selective nitric oxide synthase
inhibitor L-NAME was infused at a final concentration of 100 M for 15 min, after which,
another CRH was induced. CRH responses before and after L-NAME infusion were analyzed
and compared.

Statistical and Data Analyses:
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Flow debt (baseline flow rate multiplied by occlusion duration) and repayment volume (the
integral of hyperemic area above the baseline flow) were calculated using “the integral relative to
baseline” function in the data pad of Lab-Chart 7.0 software. Since absolute coronary flow rates
change proportionally with heart mass, the repayment volume and flow debt are presented as
mL/g wet heart weight, and baseline and peak flow rate data are presented as (mL. min –1.g wet
heart weight–1). Values are means ± SE; n represents the number of animals. For data analysis,
two-tailed unpaired t-tests were used for unpaired data analysis, repeated measures ANOVAs
were used for populations measured 3 times, and two-way ANOVAs were used to compare data
between groups. Differences were considered statistically significant when p≤0.05. Post hoc
power analyses for the main results in each experiment were calculated using G*Power 3.1.9.2.
software (Heinrich Heine, Universität Düsseldorf).

Results
CRH Response:
Baseline function of sEH–/– and sEH+/+ mouse hearts: Baseline functional data of isolated
mouse hearts were recorded after stabilization (between 30–40 min) before starting the
experimental protocol. There was no statistically significant difference in body weight, heart
weight, heart-to-body weight ratio, baseline coronary flow, LVDP (left-ventricular developed
pressure), and heart rate between sEH+/+ and sEH–/– mice (Table 1).

Role of sEH in CRH:
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Comparison of repayment volume between female and male sEH+/+ and sEH–/– mice showed no
statistically significant differences between female (F) and male (M) sEH+/+mice (p>0.05) or
between female (F) and male (MsEH–/–) mice (p>0.05) (Fig. 1). However, M-sEH–/– had more
enhanced (p=0.04, Fig. 1) repayment volume compared to M-sEH+/+. Also, F-sEH–/– had more
enhanced (p=0.01, Fig. 1) repayment volume compared to F-sEH+/+. The post hoc power
analysis for repayment volume was 77.7%. Due to the lack of sex difference in CRH response,
we used equal ratios of male and female mice from each strain for the remainder of the study.
Figure 2 presents CRH comparison between sEH+/+ and sEH–/– mice. Repayment volume in sEH–
/–

was 28% higher compared to sEH+/+ mice (7.7 ± 0.4 and 6.0 ± 0.2 mL/g respectively, p<0.001,

Fig. 2B) and the repayment/debt ratio was also 32% higher in sEH–/– compared to sEH+/+ mice
(2.0 ± 0.1 and 1.5 ± 0.1 respectively, p<0.001, Fig. 2C). The post hoc power analysis for the
repayment volume was 96.8%. Repayment duration (Fig. 2D), baseline coronary flow (CF), leftventricular developed pressure (LVPD) and heart rate (HR) were not significantly different
between the two groups.

Oxylipins Analysis in Heart Perfusate Samples:
Heart perfusate oxylipin levels were determined by LC–MS/MS. Perfusate samples were
collected at baseline after stabilization and after the 15 sec ischemia in sEH+/+ and sEH–/– mice.
Out of the four regioisomers of EETs, only 14,15-EET and its corresponding metabolite (14,15DHET) were detected. As expected, 14,15-EET was increased by 2.5 fold (p<0.001), whereas
14,15-DHET was decreased (p<0.001) in sEH–/– vs. sEH+/+ mice at baseline and post-ischemia
(Fig. 3A). As a result, the 14,15-EET/DHET ratio was increased in sEH–/– vs. sEH+/+ mice
(p<0.001, Fig. 3B). The post hoc power analysis for the 14,15-EET/DHET ratio was 94.5%.
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There was no difference in either metabolite pre- or post-ischemia within the same strain (Fig.
3).

Our LC–MS/MS also detected 4 regioisomers of mid-chain HETEs: 5-, 11-, 12-, and 15HETEs. All detected HETEs (5-, 11-, 12-, and 15-HETE) were significantly decreased in postischemia compared to baseline in both sEH–/– and sEH+/+ mice (p=0.02, p=0.04, p=0.05, and
p=0.03 respectively, Fig. 4A-D), except for 12-HETE in sEH+/+ mice, which did not reach
significance. There was no difference in any of the measured HETE metabolites between sEH–/–
and sEH+/+ mice (Fig. 4A-D). The post hoc power analysis for 5-, 11-, 12-, and 15-HETEs was
56%, 48%, 48%, and 73% respectively.

The 9,-10-epoxyoctadecaenoic acid (9,10-EpOME) was increased by 118% at baseline in
sEH–/– versus sEH+/+ mice (Fig. 5A, p=0.03), but not post-ischemia (Fig. 5A, p>0.05), whereas
12,13-EpOME was increased by 116% at baseline and 46% post-ischemia in sEH–/– vs. sEH+/+
mice (Fig. 5A, p=0.03). However, 9,10- and 12,13-DiHOMEs, dihydroxyoctadecaenoic acids,
were decreased by 59% and 77%, respectively, at baseline (p<0.01), and by 48% and 76%,
respectively, post-ischemia (Fig. 5B, p<0.001) in sEH–/– vs. sEH+/+ mice. Interestingly, a
decreasing trend in EpOMEs post-ischemia compared to baseline was observed in sEH–/– mice,
but was not statistically significant (Fig. 5A, p=0.21). As a result, 9,10-EpOME/DiHOME and
12,13-EpOME/DiHOME ratios were increased at baseline (Fig. 5C, p<0.01), and post-ischemia
(Fig. 5C, p<0.01). The post hoc power analysis for 9,10-EpOME/DiHOME and 12,13EpOME/DiHOME ratios were 88%, and 89% respectively. Additionally, analysis of HODEs
showed an increase in 13-HODE, but not 9-HODE, in sEH–/– vs. sEH+/+ mice at baseline and
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post-ischemia (Fig. 6, p<0.01). The post hoc power analysis for 13-HODE analysis was 79%.
There was no statistically significant change in EpOMEs, DiHOMEs, or HODEs pre- and postischemia within the same group (Fig. 5, 6, p>0.05).

Effect of PPAR-antagonist (T0070907) on CRH:
Administering T0070907 decreased CRH in both sEH+/+ and sEH–/– mice (Fig. 7A-C). In sEH+/+
mice, repayment volume (RV) was decreased by 25% (from 5.8 ± 0.5 to 4.3 ± 0.3 mL/g,
p<0.001, Fig. 7A), repayment/debt (R/D) ratio was decreased by 14% (from 1.4 ± 0.1 to 1.2 ±
0.1, p<0.01, Fig. 7B), repayment duration (RD) was decreased by 54% (from 2.4 ± 0.3 to 1.1 ±
0.2 min, p=0.02 Fig. 7C). Similarly, in sEH–/– mice, repayment volume was decreased by 33%
(from 7.9 ± 0.8 to 5.7 ± 0.8 mL/g, p<0.01, Fig. 7A), repayment/debt ratio was decreased by 32%
(from 2.2 ± 0.4 to 1.5 ± 0.2, p=0.01, Fig. 7B), and repayment duration was decreased by 54%
(from 2.8 ± 0.3 to 1.3 ± 0.1 min, p<0.01, Fig. 7C). Comparing CRH responses between sEH–/–
and sEH+/+ mice without T0070907: repayment volume and repayment/debt ratio were increased
more in sEH–/– vs. sEH+/+ mice (p<0.05 and p=0.04 respectively, Fig. 7A & 7B). The post hoc
power analysis for the repayment volume was 76%. In both sEH+/+ and sEH–/– mice, baseline CF,
peak PHF, HR and LVDP were not changed by T0070907 (P>0.05, Fig. 7D-F).

Effect of PPAR-agonist (rosiglitazone) on CRH:
Infusion of rosiglitazone increased CRH in both sEH+/+ and sEH–/– mice. In sEH+/+ mice,
repayment volume (RV) was increased by 37% (from 6.1 ± 0.4 to 8.4 ± 1.3 mL/g, p=0.04, Fig.
8A), repayment duration (RD) was increased by 38% (from 2.1 ± 0.3 to 2.9 ± 0.4 min, p=0.05,
Fig. 8C), and baseline coronary flow (CF) was increased by 13% (from 15.1 ± 0.2 to 17.1 ± 0.9
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mL/min/g, p=0.03, Fig. 8D). Although repayment/debt (R/D) ratio was increased by 25% (from
1.6 ± 0.1 to 2.0 ± 0.4), it was not statistically significant (Fig. 8B). Likewise, in sEH–/– mice,
rosiglitazone increased repayment volume by 37% (from 7.6 ± 0.5 to 10.4 ± 1.1 mL/g, p=0.04,
Fig. 8A), repayment duration was increased by 50% (from 2.0 ± 0.1 to 3.0 ± 0.3 min, p=0.01,
Fig. 8C), and baseline coronary flow (CF) was increased by 9% (from 14.0 ± 0.6 to 15.2 ± 0.7
mL/min/g, p=0.04, Fig. 8D). Repayment/debt ratio was also increased by rosiglitazone (from 2.2
± 0.1 to 2.7 ± 0.3), but was not statistically significant (p>0.05, Fig. 8B). Comparison of CRH
responses between sEH–/– and sEH+/+ mice without rosiglitazone: repayment volume and
repayment/debt ratio were increased more in sEH–/– vs. sEH+/+ (p=0.02 and p=0.05 respectively,
Fig. 8A & 8B). The post hoc power analysis for the repayment volume was 87%. In both sEH+/+
and sEH–/– mice, PHF, HR and LVDP were not changed by rosiglitazone (p>0.05, Fig. 8E &
8F).

Effect of L-NAME on CRH:
Administering L-NAME decreased CRH in both sEH+/+ and sEH–/– mice. No statistically
significant difference was observed between L-NAME-infused sEH+/+ and L-NAME-infused
sEH–/– mice (p=0.36, Fig. 9A-C) In sEH+/+ mice, L-NAME decreased repayment volume (RV)
by 43% (from 6.5 ± 0.6 to 3.7 ± 0.3 mL/g, p<0.01, Fig. 9A), decreased repayment duration (RD)
by 47% (from 1.7 ± 0.2 to 0.9 ± 0.1 min, p<0.01, Fig. 9C), decreased baseline CF by 36% (from
14.1 ± 0.7 to 9.0 ± 0.9 mL/min/g, p<0.001, Fig. 9D), decreased peak hyperemic flow (PHF) from
34.4 ± 0.8 to 31.2 ± 0.7 mL/min/g (p<0.01, Fig. 9E), and decreased heart rate (HR) from 366.7 ±
10.1 to 338.5 ± 18.5 beat/min (p=0.01, Fig. 9F). Repayment/debt (R/D) ratio (Fig. 9B) and
LVDP (data not shown) were not different between the two groups. Similarly, in sEH–/– mice, L-
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NAME decreased repayment volume by 54% (from 8.9 ± 1.3 to 4.1 ± 0.3 mL/g, p<0.01, Fig.
9A), decreased repayment/debt ratio by 26% (from 2.7 ± 0.3 to 2.0 ± 0.1, p=0.03, Fig. 8B),
decreased repayment duration by 61% (from 2.3 ± 0.2 to 0.9 ± 0.1 min, p<0.001, Fig. 9C), and
decreased baseline CF by 36% (from 13.5 ± 0.9 to 8.6 ± 0.9 mL/min/g, p<0.001, Fig. 9D), PHF,
HR and LVPD were not significantly changed by L-NAME (Fig. 9E & F). Comparing CRH
responses between sEH–/– and sEH+/+ mice without L-NAME treatment: repayment volume and
repayment duration were increased more in sEH–/– vs. sEH+/+ mice (p=0.01 and p=0.01
respectively, Fig. 9A & C). The post hoc power analysis for the repayment volume was 97%.
We summarized our observed results into a proposed schematic diagram (Fig. 10).

Tables, Figures, and Figure Legends:
sEH

+/+

sEH

-/-

Age, weeks

14.6 ± 0.3

14.7 ± 0.4

Body weight, g

22.7 ± 1.1

24.3 ± 1.5

Heart weight, mg

109 ± 7.0

121 ± 10.0

0.48 ± 0.01

0.49 ± 0.01

15.7 ± 0.6

16.5 ± 0.8

109.6 ± 10.0

115.0 ± 12.3

414 ± 11

396 ± 6

Heart-to-body weight ratio, %
-1

-1

Coronary flow, ml.min .g
LVDP, mmHg
Heart rate, beat.min

-1

Table 1.1: Baseline functional data for wild type (sEH+/+) and sEH-null (sEH–/–) isolated mouse
heart. n = 12 per group.
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Figure 1.1: Comparison of repayment volume (RV) between female and male wild type (sEH+/+)
and sEH–/– (sEH-null) mice. Repayment volume was not significantly different between female
(F-sEH+/+) and male (M-sEH+/+) WT mice (p>0.05) and between female (F-sEH–/–) and male (MsEH–/–) sEH-null mice (p>0.05). However, M-sEH–/– had more enhanced (p=0.04) repayment
volume compared to M-sEH+/+. Also, F-sEH–/– had more enhanced (p=0.01) repayment volume
compared to F-sEH+/+. * p≤0.05 vs. baseline F-sEH+/+. # p≤0.05 vs. M-sEH+/+. n = 6 per group.
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Figure 1.2: Comparison of coronary reactive hyperemia (CRH) between wild type (sEH+/+) and
sEH–/– (sEH-null) mice. (A) tracing depicting coronary flow changes at baseline (before CRH)
and after CRH was induced by 15-second no-flow ischemia in both sEH+/+ (dash line) and sEH–/–
(continuous line) mice. Repayment volume (B, p<0.001) and repayment/debt ratio (C, p=0.0004)
were enhanced in sEH–/– vs. sEH+/+ mice. Repayment duration (D) was increased in sEH–/– vs.
sEH+/+, but didn’t reach statistical significance (p=0.31). Peak hyperemic flow, baseline CF, leftventricular developed pressure (LVDP) and heart rate (HR) were not significantly different
between the two groups (data not shown). * p≤0.05 sEH+/+. n = 12 per group.
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Figure 1.3: LC - MS/MS analysis for 14, 15 – EETs and 14,15-DHETs in sEH+/+ and sEH–/–
mice heart perfusate at baseline (pre-ischemia) and directly after 15-second ischemia (postischemia). (A) At baseline and post-ischemia, 14,15-EET was increased 2.5 fold in sEH–/– vs.
sEH+/+ mice (p<0.001) whereas 14,15-DHET was decreased (p<0.001). There was no difference
in either metabolite pre- and post-ischemia within the same strain. (B) Ratio between 14,15-EET
to 14,15-DHET was increased at baseline and post-ischemia in sEH–/– vs. sEH+/+ mice (p<0.001).
* p≤0.05 vs. baseline sEH+/+. # p≤0.05 vs. post-ischemia sEH+/+. n = 7 sEH+/+, n = 10 sEH–/–.
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Figure 1.4: LC - MS/MS analysis of HETEs in sEH+/+ and sEH–/– heart perfusate at baseline
(pre-ischemia) and directly after 15-second ischemia (post-ischemia). All detected HETEs (5-,
11-, 12-, and 15-HETE), were decreased post-ischemia (after perfusion was reinstated) compared
to baseline in both sEH+/+ and sEH–/– mice (p=0.02, p=0.04, p=0.05, p=0.03 respectively, A-D).
Only 12-HETE in sEH+/+ mice did not reach statistically significant level (p=0.09). There was no
difference in any of the measured HETEs between sEH+/+ and sEH–/– mice (p>0.05). * p≤0.05 vs.
baseline sEH+/+. # p≤0.05 vs. baseline sEH–/–. n = 7 sEH+/+, n = 10 sEH–/–.
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Figure 1.5: LC-MS/MS analysis of EpOMEs and DiHOMEs in sEH+/+ and sEH–/– mouse heart
perfusate samples at baseline (pre-ischemia) and directly after 15-second ischemia (postischemia). (A) 9,10-EpOME was increased at baseline (p=0.03) and post-ischemia, but was not
statistically significant (p=0.21), whereas 12,13-EpOME was increased both at baseline and postischemia (p=0.03) in sEH–/– vs. sEH+/+ mice. (B) 9,10- and 12,13-DiHOMEs were decreased at
baseline (p=0.001), and post-ischemia (p<0.001) in sEH–/– vs. sEH+/+ mice. A decreasing trend in
EpOMEs post-ischemia compared to baseline was observed in sEH–/– mice, but was not
statistically significant. (C) 9,10- and 12,13-EpOME/DiHOME ratios were increased at baseline
(p=0.002), and post-ischemia (p=0.0008). * p≤0.05 vs. baseline sEH+/+. # p≤0.05 vs. postischemia sEH+/+. n = 7 sEH+/+, n = 10 sEH–/–.
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Figure 1.6: LC-MS/MS analysis of HODEs in sEH+/+ and sEH–/– mouse heart perfusate samples
at baseline (pre-ischemia) and directly after 15-second ischemia (post-ischemia). Baseline and
post-ischemia analysis 9- and 13-HODEs in sEH–/– vs. sEH+/+. 13-HODE, but not 9-HODE, was
increased in sEH–/– vs. sEH+/+ mice at baseline and post-ischemia (p=0.006). There was no
change in either HODEs before and after ischemia in both groups (p>0.05). * p≤0.05 vs. baseline
sEH+/+. # p≤0.05 vs. post-ischemia sEH+/+. n = 7 sEH+/+, n = 10 sEH–/–.
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Figure 1.7: Effect of PPAR-antagonist (T0070907, 10 M) on CRH in sEH+/+ and sEH–/– mice.
Infusion of T0070907 decreased CRH in both sEH+/+and sEH–/– mice. In sEH+/+ mice, T0070907
decreased repayment volume (RV) by 25% (A, p<0.001), repayment/debt (R/D) ratio by 14% (B,
p=0.004), and repayment duration (RD) by 54% (C, p=0.02). In sEH–/–, T0070907 decreased RV
by 33% (A, p=0.0039), repayment/debt ratio by 32% (B, p=0.01), and RD by 54% (C, p=0.003).
Comparing sEH–/– and sEH+/+ mice: repayment volume and repayment/debt ratio were increased
more in sEH–/– vs. sEH+/+ mice (A, p=0.048 and B, p=0.04 respectively). In both sEH+/+ and
sEH–/– mice, baseline CF (D), PHF (E), HR (F), and LVDP (data not shown) were not changed
by T0070907. * p≤0.05 vs. sEH+/+. # p≤0.05 vs. sEH–/–. n = 6 per group.
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Figure 1.8: Comparison CRH for wild type (sEH+/+) mice before and after infusion of
rosiglitazone (PPAR-agonist, 10M); administration of rosiglitazone increased CRH in both
sEH+/+and sEH–/– mice. In sEH+/+ mice, repayment volume (RV) was increased by 37% (A,
p=0.04), repayment/debt ratio (R/D) by 38% (B, p=0.03), repayment duration (RD) by 38% (C,
p=0.05), and baseline coronary flow (CF) (D, p=0.0280). In sEH–/– mice, rosiglitazone increased
RV by 37% (A, p=0.04), repayment/debt ratio (R/D) by 23% (B, p=0.03), RD by 50% (C,
p=0.01), and baseline coronary flow (CF) (D, p=0.04). Comparing sEH–/– and sEH+/+ mice: RV
and R/D were increased more in sEH–/– vs. sEH+/+ mice (p=0.02 and p=0.05 respectively). In
both sEH+/+ and sEH–/– mice, PHF (E), HR (F), and LVDP (data not shown) were not
significantly changed by rosiglitazone. * p≤0.05 vs. sEH+/+. # p≤0.05 vs. sEH–/–. n = 6 sEH+/+, n
= 7 sEH–/–.
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Figure 1.9: Comparison of the effect of L-NAME (nitric oxide synthase inhibitor) on coronary
reactive hyperemia (CRH) in sEH-null (sEH–/–) and sEH+/+ mice before and after infusion of LNAME (100 M). L-NAME decreased CRH in both sEH+/+ and sEH–/– mice, and CRH responses
between the two groups were not statistically significant (p=0.36). In sEH+/+, L-NAME
decreased repayment volume (RV) by 43% (A, p=0.002), repayment duration (RD) by 47% (C,
p=0.002), baseline CF by 36% (D, p<0.001), peak hyperemic flow (PHF) (E, p=0.001), and heart
rate (HR) (F, p=0.01). Repayment / debt (R/D) ratio (B) and LVDP (not shown) were not
different between the two groups. In sEH–/– mice, L-NAME decreased RV by 54% (A, p=0.005),
R/D ratio by 26% (B, p=0.03), RD by 61% (C, p<0.001), and baseline CF by 36% (D, p<0.001),
PHF (E), HR (F) and LVPD (not shown) were not significantly changed by L-NAME. RV and
RD were increased more in untreated sEH–/– vs. untreated sEH+/+ mice (A, p=0.01 and C, p=0.01
respectively). n = 8 per group.
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Figure 1.10: A schematic diagram comparing the changes observed for selected oxylipins in
response to short-lived ischemia and their possible impact on coronary reactive hyperemia
(CRH) between sEH–/– and sEH+/+ mice. sEH deletion enhanced CRH possibly through increased
14,15-EET/DHET ratio, increased 13-HODE, increased EpOME/DiHOME ratio. Role of NO,
PPARγ and mid-chain HETEs was comparable in both sEH–/– and sEH+/+ mice.
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Discussion
Global deletion of soluble epoxide hydrolase (sEH–/–) in mice shows an increase in
coronary reactive hyperemia (CRH) in isolated heart model after a brief ischemia. The observed
changes in oxylipins associated with sEH-deletion (increased EETs/DHETs, increased
EpOMEs/DiHOMEs, and increased HODEs) could be involved in enhancing CRH. The
relationship between sEH deletion, oxylipins, PPARγ, and CRH in isolated mouse hearts is
unknown. Therefore, we designed this study to investigate the role of sEH-deletion, and the
associated changes in various oxylipins, in the modulation of CRH using sEH–/– and sEH+/+
mice. Our data demonstrate that, compared with sEH+/+, sEH–/– mice had: 1) increased CRH; 2)
increased 14,15-EET/DHET ratio; 3) increased EpOMEs/DiHOMEs ratio; and 4) increased 13HODE. Also, both sEH+/+ and sEH–/– mice had: 1) comparable role of PPARγ in mediating CRH;
2) similar response to L-NAME-mediated decrease in CRH; and 3) similar decrease in mid-chain
HETEs post-ischemia.

In this study, sEH deletion in mice (sEH–/– mice) was associated with a statistically significant
increase in CRH after a brief ischemia compared to sEH+/+ mice. Interestingly, there was no
difference in CRH, as measured by repayment volume, between male and female mice in either
strain (sEH–/– and sEH+/+). This contrasts to the sex difference in vascular response between
male (M-sEH+/+) and female (F-sEH+/+) wild type mice, where F-sEH+/+ exhibited increased
flow/shear stress-induced dilator response (FID) in isolated gracilis muscle arterioles compared
to M-sEH+/+ (73); In addition, Qin et al., (73) reported that sEH deletion in male (M-sEH–/–)
enhanced FID to a level comparable to that observed in F-sEH–/– and female F-sEH+/+.
Therefore, the authors suggested that deletion of sEH abolished the sex difference in FID
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response observed in wild type mice (73). But, in our study, we did not observe any sex
difference in CRH response. Although we used the same mouse strains (sEH–/– and sEH+/+) Qin
et al. used in their study, the lack of sex difference in CRH response in our study was probably
due to different tissues studied (isolated mouse heart versus leg gracilis muscle’s second order
arterioles (73)) and the different triggering factor for vasodilation (CRH in response to ischemia
versus FID (73)).
CRH may be viewed as a protective mechanism, and is attenuated in pathologic
conditions. For example, CRH is decreased in cardiac hypertrophy (36), metabolic syndrome
(6), unstable angina, myocardial infarction, congestive heart failure and cardiac death (30). Out
of the four EET isomers, only 14,15-EET was detected in the heart perfusate samples by LCMS/MS. The other EET isomers (5,6-, 8,9-, and 11,12-EETs) were not detected possibly
because their level was lower than the level of 14,15-EET and lower than the detection power of
the LC-MS/MS. In support of this speculation, Li et al. (45) reported that the level of 14,15-EET
was approximately 3 time higher than that of 5,6-, 8,9-, and 11,12-EETs isomers in mouse
plasma samples. Our results demonstrate that in sEH–/– mice 14,15-EET/DHET ratio was
increased. EETs are well established as substrates for sEH (55, 62). Also, in the presence of
sEH, EETs are rapidly converted by hydration to their corresponding DHETs resulting in loss
of the beneficial cardiovascular effects of these epoxyeicosanoids (53, 59, 85, 102). Evidently,
disruption of sEH causes EETs to accumulate, be retained for longer periods, and to continue to
exert their beneficial effects (19, 59). Besides the main, sEH-catalyzed, breakdown pathway,
EETs can be broken down through other minor pathways, such as -oxidation, -oxidation, and
chain elongation. The latter two pathways become more important when sEH activity is
inhibited or deleted (32). None of these minor pathways has been studied or considered in our
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study. EETs also exert cardioprotective effects in ischemia/reperfusion injury (77). Deletion of
sEH gene increases endogenous EETs by decreasing the metabolic conversion of EETs into
the less-active DHETs. Our results suggest that CRH increases in mice due to sEH deletion,
which is shown here to be associated with an increase in 14,15-EET/14,15-DHET ratio without
changing baseline coronary flow, heart rate, and left-ventricular developed pressure.

This study also showed that CRH in sEH+/+ and sEH–/– mouse hearts was attenuated by
T0070907 (PPARγ-antagonist), but enhanced by rosiglitazone (PPARγ-agonist). These results
from PPARγ-antagonist and PPARγ-agonist experiments suggest that PPARγ receptors are
involved in modulating CRH. Interestingly, our lab reported that sEH–/– mouse aorta had
increased expression of PPARγ protein and enhanced vascular relaxation compared to sEH+/+
mice (59). Liu et al. suggested that selective sEH inhibition potentiated the anti-inflammatory
effect in endothelial cells, presumably by increasing the retention of EETs, which would
activate PPAR (46). These studies indicate that EETs’ effects could be mediated by
PPARγ receptors. However, our results did not show the same relationship; the effect
of T0070907 and rosiglitazone were comparable between sEH+/+ and sEH–/– mice. Therefore,
we found that CRH in sEH+/+ and sEH–/– mice may similarly be mediated by PPAR.

Infusion of L-NAME, a non-selective NO synthase inhibitor, decreased CRH in both
sEH+/+ and sEH–/– mice in the present study. These data suggest that the presence or absence of
sEH does not have any specific effect on L-NAME-induced attenuation of CRH response in
both sEH+/+ and sEH–/– mice. Similarly, Zhang et al. described that the inhibition of the activity
of sEH enzyme ameliorates endothelial dysfunction in the db/db mice, which is NO-
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independent, but dependent on cyp450-epoxygenase-derived metabolites (EETs) (103). Our
studies have shown that vascular relaxation through A2AAR was independent of NO and
cyclooxygenase pathways (57, 58, 60). Also, others (17, 39, 45) reported that sEH–/– mice
were associated with elevated EETs levels compared to sEH+/+ mice, and these EETs exerted
cardioprotective effects against ischemia/reperfusion injury (77). Therefore, the enhanced CRH
in sEH–/– compared to sEH+/+ mice seems to be independent of the NO pathway, but dependent
on the changes associated with sEH-deletion. Although cyclooxygenase (COX) pathway was
found to be involved in myocardial reactive hyperemia in dogs, and a cross-talk between COX
and nitric oxide pathways in dog coronary vessels was suggested (72), a later publication by
Hellmann et al. (27) suggested that COX-metabolites, prostanoids, were not involved in reactive
hyperemia in human skin. Accordingly, the role of prostanoids in mouse CRH was not
investigated in our study, and therefore, cannot be ruled out.

In addition to the increase in 14,15-EET/DHET ratio in sEH–/– mice, 13-hydroxylated
linoleic acid (13-HODE, hydroxyoctadecadienoic acid) was also increased in sEH–/– versus
sEH+/+. 13-HODE may play an anti-inflammatory role and may act as a PPARγ-agonist in
inflammatory diseases as reported by others (2, 4, 18, 21, 88). Also, Guido et al., (15) reported
that 13-HODE was involved in canine splenic as well as coronary artery relaxation through
prostacyclin (PGI2) biosynthesis in both endothelial and smooth muscle cells. Also, in the
present study, no change was observed in 9-HODE (hydroxyoctadecadienoic acid), which is
considered pro-inflammatory, activating G protein coupled receptor and JNK (26, 66) in both
sEH–/– and sEH+/+ mice. Therefore, an increase in 13-HODE in sEH–/– mouse heart perfusate
may possibly have a role in enhancing CRH.
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Other linoleic acid metabolites, such as 9,10-,12,13-EpOMEs (epoxyoctadecaenoic acid)
and 9,10-,12,13-DiHOMEs (dihydroxyoctadecaenoic acids) were detected in sEH+/+ and sEH–/–
mouse heart perfusate in the current study. The increased EpOMEs/DiHOMEs ratios was the
result of increased EpOMEs and decreased DiHOMEs in sEH–/– versus sEH+/+ mice. In support
of our data, Lee et al. (44) reported that EpOMEs/DiHOMEs ratios were increased in response to
sEH inhibition by AUDA in vivo, and improved renal recovery against ischemia/reperfusion
injury in C57BL/6 mice. Not only that, Nowak et al., (65) reported that primary cultures of rabbit
renal proximal tubular cells (RTPC) were protected by the pretreatment of 12,13-EpOME against
hypoxia/reoxygenation injury whereas, 12,13-DiHOME did not have a protective effect. Based
on our findings, the increase in EpOMEs/DiHOMEs ratio in sEH–/– mouse heart perfusate may
possibly play a role in enhancing CRH along with increased 14,15-EET/DHET ratio and 13HODE.

Interestingly, 5-, 11-, 12-, and 15-HETEs (hydroxyeicosatetraenoic acids) data in the
current study demonstrate a significant impact after 15-second ischemia. Surprisingly, there was
no change in the level of these mid-chain HETEs between sEH–/– and sEH+/+ mice. Mid-chain
HETEs (5-, 11-, 12-, and 15-HETEs) are arachidonic acid (AA)-derived metabolites produced by
allylic oxidation of AA by the action of lipoxygenase (LOX) (39). Increased formation of these
mid-chain HETEs is involved in cardiovascular dysfunction through endothelial cells, smooth
muscle cells, and monocytes (13, 68, 87, 97). These mid-chain HETEs had direct chemo-toxic
effects on vascular tone and on the production of endothelial vascular factors (29, 56, 86, 93).
Our data show that 5-, 11-, 12-, and 15-HETEs were significantly decreased after a brief
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ischemia of 15-seconds in both sEH–/– and sEH+/+ mice. In contrast to our findings, Li et al.
reported that the plasma levels of 5-, 9-, 11-, and 15-HETEs were elevated in sEH–/– compared to
sEH+/+ mice (45). This discrepancy could be explained by the different source of the samples;
ours were from the isolated heart perfusate, whereas theirs were from the plasma (45).
Nevertheless, CRH was enhanced more in sEH–/– compared to sEH+/+ mice. Based on the
described effects of these mid-chain HETEs, CRH response to brief ischemia in both sEH–/– and
sEH+/+ mice may have been enhanced by the decrease in 5-, 11-, 12-, and 15-HETEs. Also,
deletion of sEH did not have an effect on the level of these HETEs in the heart perfusate
samples.

In summary, the present data suggest that there is a relationship between the increase in
coronary reactive hyperemia (CRH) and deletion of soluble epoxide hydrolase (sEH–/–) in both
male and female mice. CRH is mediated, in part, by PPARγ activation in mice, as demonstrated
by inhibition of CRH with a PPARγ-antagonist and enhanced CRH with a PPARγ-agonist.
Likewise, CRH is also dependent on nitric oxide (NO), but the enhanced CRH presented by
sEH–/– mice cannot be solely explained through changes in PPARγ or NOS. However, deletion
of sEH resulted in significant changes in several oxylipins, such as increased EETs/DHETs ratio,
increased EpOMEs/DiHOMEs ratios, and increased 13-HODE. These oxylipins are reported to
provide protection in other models of ischemia/reperfusion injury. Thus, our data suggest that
these differences in oxylipin metabolism contribute to the enhanced CRH in sEH–/– mice.
Therefore, we conclude that deletion of sEH enhances CRH through increased 14,15-EET/DHET
ratio, increased 13-HODE, and increased EpOMEs/DiHOMEs ratio.
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Perspective and Significance
These findings demonstrate that sEH-deletion is associated with significant changes in
arachidonic acid-derived metabolites (EETs), and linoleic acid-derived metabolites (EpOMEs,
DiHOMEs, and HODEs). Any dysregulation in these oxylipins signaling pathways or
allelic variations may possibly lead to disturbances in regular coronary circulation and may
have clinical implications (42, 43), such as coronary artery disease in humans with blunted or
compromised hyperemic response. Current findings suggest that deletion of sEH, enhances CRH
through

increased

14,15-EET/DHET

ratio,

increased

13-HODE,

and

increased

EpOMEs/DiHOMEs ratio. Therefore, targeting sEH through pharmacology could be a feasible
option for clinical implementation in cardiovascular diseases in which the hyperemic response is
blunted or compromised.
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CHAPTER TWO

Effect of Soluble Epoxide Hydrolase Inhibition on Coronary Reactive Hyperemia: Role of
Oxylipins and PPAR
(This chapter was published in PLoS One journal)
(2016 Sep 1;11(9):e0162147. doi: 10.1371/journal.pone.0162147. eCollection 2016.
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Abstract:
Coronary reactive hyperemia (CRH) is a physiological response to ischemic insult that prevents
the potential harm associated with an interruption of blood supply. The relationship between the
pharmacologic inhibition of soluble epoxide hydrolase (sEH) and CRH response to a brief
ischemia is not known. sEH is involved in the main catabolic pathway of epoxyeicosatrienoic
acids (EETs), which are converted into dihydroxyeicosatrienoic acids (DHETs). EETs protect
against ischemia/reperfusion injury and have numerous beneficial physiolgical effects. We
hypothesized that inhibition of sEH by t-AUCB enhances CRH in isolated mouse hearts through
changing the oxylipin profiles, including an increase in EETs/DHETs ratio. Compared to
controls, t-AUCB–treated mice had increased CRH, including repayment volume (RV),
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repayment duration, and repayment/debt ratio (p ≤ 0.05). Treatment with t-AUCB significantly
changed oxylipin profiles, including an increase in EET/DHET ratio, increase in
EpOME/DiHOME ratio, increase in the levels of HODEs, decrease in the levels of mid-chain
HETEs, and decrease in prostanoids (p ≤ 0.05). Treatment with MS-PPOH (CYP epoxygenase
inhibitor) reduced CRH, including RV (p ≤ 0.05). Involvement of PPAR in the modulation of
CRH was demonstrated using a PPAR-antagonist (T0070907) and a PPAR-agonist
(rosiglitazone). T0070907 reduced CRH (p ≤ 0.05), whereas, rosiglitazone enhanced CRH (p ≤
0.05) in isolated mouse hearts compared to the non-treated. These data demonstrate that sEH
inhibition enhances, whereas CYP epoxygenases-inhibition attenuates CRH, PPARγ mediate
CRH downstream of the CYP epoxygenases-EET pathway, and the changes in oxylipin profiles
associated

with

sEH-inhibition

collectively
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contributed

to

the

enhanced

CRH.

Introduction
Cytochrome P450 (CYP) epoxygenases catalyze the epoxidation of arachidonic acid (AA) to
form epoxyeicosatrienoic acids (EETs). Produced in endothelial cells, EETs have numerous
biological functions, including hyperpolarization and relaxation of vascular smooth muscle cells
by activating large conductance Ca2+-activated K+ channels (BKCa) (9, 20). EETs are rapidly
metabolized through hydration by soluble epoxide hydrolase (sEH) to the less active
dihydroxyeicosatrienoic acids (DHETs). Although hydration by sEH is the main catabolic
pathway of EETs (83), two EET isomers, 5,6- and 8,9-EET, are substrates for the
cyclooxygenase (COX) pathway (32). Different strategies can increase the levels of EETs to
study their effects, including transgenic models (17, 59, 77) and pharmacologic targeting of sEH
(61) or CYP epoxygenases (69). EET generation was increased in CYP2J2–over-expressed
mouse myocytes and shown to exert cardioprotective effects against ischemia/reperfusion injury
(77). In addition to EETs, targeting sEH impacts the levels of oxylipins (epoxyoctadecaenoic
acids [EpOMEs], dihydroxyoctadecaenoic acids [DiHOMEs], hydroxyoctadecadienoic acids
[HODEs], hydroxyeicosatetraenoic acids [HETEs], and prostanoids) (45, 47, 75, 76). Lee et al.
reported that sEH inhibition by AUDA was associated with an increased EpOME/DiHOME ratio
and improved renal recovery against ischemia/reperfusion injury in C57BL/6 mice (44). 13HODE enhanced prostacyclin (PGI2) biosynthesis and was involved in splenic and coronary
artery relaxation in Mongrel dogs (15). Also, mid-chain HETEs had direct chemo-toxic effects
on vascular tone and on the production of endothelial vascular factors (29, 56, 86, 93). Further,
studies indicated that EET biological effects could be mediated by peroxisome proliferatoractivated receptor-gamma (PPARγ) (8, 14, 46, 70). For example, EET-induced aortic relaxation
in mice was mediated by PPAR (59, 70).
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When the heart is subjected to a brief period of ischemia, it responds by momentarily increasing
coronary blood flow (12), known as reactive hyperemia (RH) or coronary RH (CRH). The
phenomenon of CRH is associated with significant coronary vasodilation in response to a
cessation in coronary perfusion. Ischemic insult is associated with potentially detrimental effects
on cardiac function. Increased blood flow associated with CRH prevents or decreases injury or
damage due to ischemia. By supplying an increased amount of blood to the deprived heart
muscle, CRH speeds up functional recovery and washes away accumulated metabolic byproducts
(105). CRH is considered a protective mechanism, which is blunted or compromised in
pathologic conditions affecting the coronary circulation, including cardiac hypertrophy (36),
metabolic syndrome (6), unstable angina, myocardial infarction, and congestive heart failure
(30). The metabolic mediators involved in RH have been studied extensively, and include
adenosine (5, 36, 37), nitric oxide (NO) (36), KATP channels (36) and hydrogen peroxide (H2O2)
(36, 80).

The potential effects of pharmacologic inhibition of CYP epoxygenases, inhibition of sEH, and
associated changes in oxylipin profiles on CRH in response to a short period of ischemia have
not been investigated. We hypothesized that inhibition of sEH enhances CRH through
modulation in oxylipin profiles and PPARγ, whereas inhibition of CYP epoxygenases attenuates
CRH in isolated mouse hearts.
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Materials and Methods
Animals
The generation of sEH null (sEH–/–) mice was described by Sinal et al. (83). sEH–/– and wildtype
(WT, sEH+/+) mice were of the C57BL/6 genetic background and provided by Dr. Darryl Zeldin,
National Institute of Environmental Health Sciences/National Institutes of Health (NIH). All
animal care and experimentation protocols were submitted to, approved, and carried out in
accordance with the West Virginia University Institutional Animal Care and Use Committee and
were in accordance with the principles and guidelines of the NIH’s Guide for the Care and Use
of Laboratory Animals. Both male and female mice (14 –16 wks old) in equal ratio were used in
our study. Mice were maintained in cages with a 12:12 h light-dark cycle and free access to
standard chow and water.

Langendorff-Perfused Heart Preparation
There are two available Langendorff technique modes to perfuse the heart: 1) constant pressure
mode and 2) constant flow mode. In our experiments, we selected the constant pressure mode.
Because the two modes have important differences, the selection between the two is particularly
important when assessing the role of coronary regulatory mechanisms in response to changing
coronary flow (CF) conditions or pathologies, such as ischemia. The constant pressure mode is
physiologically more relevant in experiments involving ischemia, like the model in our
experiments; therefore, it was selected over the other mode (84).

Soluble epoxide hydrolase null (sEH–/–) and wild-type (WT; sEH+/+) mice (14–16 wks.) of both
sexes (equal ratios) were euthanized with sodium pentobarbital (100 mg/kg body weight intra52

peritoneally). Hearts were excised and immediately placed into heparinized (5 U/mL) ice-cold
Krebs-Henseleit buffer containing (in mM) 119.0 NaCl, 11.0 glucose, 22.0 NaHCO3, 4.7 KCl,
1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, 2.0 pyruvate, and 0.5 EDTA. After removal of the lungs and
tissue surrounding the heart, the aorta was rapidly cannulated with a 20-gauge, blunt-ended
needle and continuously perfused with 37°C buffer continuously bubbled with [95% O2] – [5%
CO2] at a constant perfusion pressure of 80 mmHg. The left atrium was excised, and a waterfilled balloon made of plastic wrap was inserted into the left ventricle through the mitral valve.
The balloon was connected to a pressure transducer for continuous measurement of left
ventricular developed pressure (LVDP) and heart rate (HR). The heart was then immersed in a
water-jacketed perfusate bath (37o C) and left to beat spontaneously. Left ventricular diastolic
pressure was adjusted to 2–5 mmHg. A flow transducer was installed above the cannulated aorta
for continuous measurement of CF with an ultrasonic ﬂow probe (Transonic Systems, Ithaca,
NY). A Power–Lab Chart data acquisition system (AD Instruments, Colorado Springs, CO) was
used for data acquisition. Heart function was allowed to stabilize for 30–40 min before initiation
of CRH. Only hearts whose CF increased by more than two fold after a 15-second total occlusion
were included in the analysis. This demonstrated that the isolated heart preparation was intact to
be included in the experiment. Hearts with persistent arrhythmias or LVDP <80 mmHg were
excluded.

Coronary Reactive Hyperemic Response
After stabilization for 30–40 minutes, baseline CF, HR, and LVDP were recorded. Hearts were
subjected to 15 seconds of total occlusion by closing the valve directly above the cannulated
heart to bring forth CRH. After CF returned to pre-CRH baseline levels, post-CRH baseline CF,
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CF tracing, peak hyperemic flow (PHF), HR, LVDP, repayment volume (RV), and repayment
duration (RD) recordings were analyzed for each isolated heart. Investigational drugs were
infused into the aortic perfusion line using a microinjection pump (Harvard Apparatus, Holliston,
MA) for 15 minutes, after which another CRH was induced and the same parameters analyzed
again. Drugs were infused at a rate equivalent to 1% of CF. The final concentrations, after
standardization of dose (0.01, 0.1, 1, & 10 M) response for the various drugs used in this study
were 10 M for T0070907 (PPAR-antagonist), rosiglitazone (PPARagonist), t-AUCB (trans4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic
University

of

California,

Davis),

and

1

M

acid
for

(a

selective

MS-PPOH

sEH-inhibitor,
(methylsulfonyl-

propargyloxyphenylhexanamide, CYP-epoxygenases inhibitor). These concentrations are the
same, or less, as used in previous studies: rosiglitazone, 10 M; (67), t-AUCB, 10 M; (104),
MS-PPOH, 1 M (60).

Effect of t-AUCB on CRH Response
After stabilization for 30–40 min, isolated WT mouse hearts were subjected to 15 sec of total
occlusion. Recordings of the first CRH (baseline CF, CF tracing, LVDP, HR, RV, PHF, and RD)
were analyzed for each heart and averaged. t-AUCB was infused at a final concentration of 10
M and 1% of CF rate for 15 min, after which another CRH was induced and the same
parameters (baseline CF, CF tracing, LVDP, HR, RV, and RD) were recorded again and
analyzed.

Effect of t-AUCB on CRH Response in sEH–/– Mice:
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To investigate the specificity of the sEH-inhibitor, t-AUCB, we evaluated its effect on CRH in
sEH–/– mouse hearts, where the sEH gene is globally deleted. We followed the same protocol
described above. CRH was induced in sEH–/– mice before and after infusing t-AUCB for 15 min.
The two CRH responses were analyzed.

LC–MS/MS Oxylipin Analysis
Levels of oxylipins (5,6-, 8,9-, 11,12- and 14,15-EET, 5,6-, 8,9-, 11,12- and 14,15-DHET, 5-, 8-,
9-, 11-, 12- and 15-HETE, 9,10- and 12,13-EpOME, 9,10- and 12,13-DiHOME, 9- and 13HODE, 6-keto prostaglandin-F16K-PG-F1], PG-F2, thromboxane B2 [TxB2], PGD2, and
PGE2) were determined in pre- and post-CRH heart perfusates of WT and t-AUCB-treated WT
mice through liquid chromatography, tandem mass spectroscopy (LC-MS/MS) as described
previously (41). Heart perfusates were collected after the first 30 min of stabilization and right
after reperfusion for 2.5 min. Hearts were immersed in 5 mL of warm (37°C) Krebs-Henseleit
buffer with 5 L of 10 M t-AUCB to block further EET breakdown by sEH. Heart perfusates
were collected two times before ischemia (baseline) and pooled together as one sample and two
times after ischemia and pooled together as another sample for LC-MS/MS analysis. Samples
were stored at –80°C until processing. Samples were spiked with 30 ng PGE2-d4, 10,11- DiHN,
and 10,11-EpHep (Cayman) as internal standards, mixed with 0.1 vol of 1% acetic acid in 50%
methanol, and extracted by serial passage through Oasis HLB C18 3mL columns (Waters,
Milford, MA, USA). Columns were washed twice with 0.1% acetic acid in 5% methanol and
eluted with methanol into glass tubes containing 6 L of 30% glycerol in methanol. The
methanol was then evaporated under a stream of nitrogen gas, and the dried tubes were frozen
and stored at –80°C until analysis. Online liquid chromatography of extracted samples was
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performed with an Agilent 1200 Series capillary HPLC (Agilent Technologies, Santa Clara, CA,
USA). Separations were achieved using a Halo C18 column (2.7 mm, 10062.1 mm; MAC-MOD
Analytical, Chadds Ford, PA), which was held at 50°C. Mobile phase A was 85:15:0.1 water:
acetonitrile: acetic acid. Mobile phase B was 70:30:0.1 acetonitrile: methanol: acetic acid. Flow
rate was 400 L/min; Gradient elution was used. Mobile phase percentage B and flow rate were
varied as follows: 20% B at 0 min, ramp from 0 to 5 min to 40% B, ramp from 5 to 7 min to 55%
B, ramp from 7 to 13 min to 64% B. From 13 to 19 min the column was flushed with 100% B at
a flow rate of 550 L/min. Samples were solvated in 50 l of 30% ethanol. The injection volume
was 10 L. Samples were analyzed in triplicate. Analyses were performed on an MDS Sciex API
3000 equipped with a TurboIonSpray source (Applied Biosystems). Turbo desolvation gas was
heated to 425°C at a flow rate of 6 L/min. Negative ion electrospray ionization tandem mass
spectrometry with multiple reaction monitoring was used for detection.

Effect of MS-PPOH (CYP epoxygenase inhibitor) on CRH Response
Isolated WT mice hearts were stabilized for 30–40 min, followed by 15 sec of total occlusion.
Recordings of the first CRH (baseline CF, CF tracing, LVDP, HR, RV, PHF and RD) were
analyzed for each heart and averaged. MS-PPOH was infused at a final concentration of 1.0 M
for 15 minutes, after which the second CRH was induced. CRHs before and after MS-PPOH
infusion were analyzed and compared.

Effect of T0070907 (PPARγ antagonist) on CRH Response
Isolated WT mouse hearts were stabilized for 30–40 min followed by 15 sec of total occlusion.
Recordings of the first CRH (baseline CF, CF tracing, LVDP, HR, RV, PHF and RD) were
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analyzed for each heart and averaged for each group, as mentioned previously. T0070907 was
infused at a final concentration of 10 M and 1% of CF rate for 15 min, after which another
CRH was induced and the same parameters (baseline CF, CF tracing, LVDP, HR, RV, and RD)
were recorded again and analyzed.

Effect of t-AUCB and T0070907 on CRH Response
In this experiment, we investigated a possible link between the role of PPARγ in CRH and
pharmacological inhibition of sEH by t-AUCB. We evaluated the effects of selective sEHinhibition on CRH followed by PPARγ-antagonist. Baseline CRH was induced in WT mice. tAUCB was infused at a final concentration of 10 M for 15 minutes, after which a second CRH
was induced. T0070907 was infused while t-AUCB was still being infused, at a final
concentration of 10 M for another 15 min, and a third CRH was induced. The three CRH
responses were analyzed and compared.

Effect of Rosiglitazone on CRH Response
After stabilization, WT mouse hearts were subjected to 15 sec of total occlusion. As described
above, baseline CRH was induced in each mouse heart. Rosiglitazone was infused at a final
concentration of 10 M for 15 min, followed by another CRH. CRHs before and after
rosiglitazone infusion were analyzed and compared.

Statistical and Data Analyses
Flow debt (baseline flow rate multiplied by occlusion duration) and RV (the integral of
hyperemic area above the baseline flow) were calculated using “the integral relative to baseline”
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function in the data pad of Lab-Chart 7.0 software. Since absolute coronary flow rates change
proportionally with heart mass, the RV and flow debt are presented as ml/g wet heart weight, and
baseline and peak flow rate data are presented as (mL.min–1.g wet heart weight–1). Values are
means ± standard error; n represents the number of animals. For data analysis, two-tailed paired
t-tests were used for paired data analysis, repeated measures ANOVAs were used for populations
measured 3 times, and two-way ANOVAs were used to compare data between groups.
Differences were considered statistically significant when p ≤ 0.05.

Results

CRH Response
Effect of t-AUCB on CRH Response in WT Mice
t-AUCB enhanced CRH in WT mice (Fig. 1A). Compared to WT mice, t-AUCB-treated WT
mice had increased RV (41%; 6.1 ± 0.5 and 8.5 ± 0.4 mL/g, respectively; p < 0.05, Fig. 1B),
increased RD (64%; 1.6 ± 0.2 and 2.7 ± 0.4, respectively; Fig. 1C), an increased repayment/debt
(R/D) ratio (36%; 1.5 ± 0.1 and 2.1 ± 0.2, respectively; p < 0.05; Fig. 1D), and slightly increased
PHF (39.7 ± 0.7 and 41.2 ± 1.0 mL/min/g respectively, p < 0.05; Fig. 1E). Baseline CF, LVPD,
and HR were not different between the two groups (p > 0.05). Time-matched control
experiments with WT mouse hearts, employing three consecutive inductions of CRH, showed no
change in the CRH response and no difference in baseline heart functions, including CF, LVDP,
and HR (data not shown).

Effect of t-AUCB on CRH Response in sEH–/– Mice

58

Using the same experimental protocol as in the preceding section, t-AUCB did not have a
significant effect on CRH in sEH–/– mice, including RV (p > 0.05, Fig. 2A), R/D (p > 0.05, Fig.
2B), RD (p > 0.05, Fig. 2C), baseline CF, PHF, HR, or LVDP (data not shown).

Oxylipin Analysis of Heart Perfusate before and after t-AUCB infusion in WT Mice
Heart perfusate oxylipin levels were determined by LC–MS/MS. Perfusate samples were
collected at baseline after stabilization and right after ischemia in WT and t-AUCB-treated WT
mice. Out of the four EET regioisomers, only 14,15-EET, its corresponding metabolite (14,15DHET), and 11,12-DHET were detected. An increasing trend in the level of 14,15-EET in tAUCB-treated WT versus WT mice was observed at baseline and post-ischemia, but was not
significant (p > 0.05, Fig. 3A). However, sEH-metabolized 14,15-DHET significantly decreased
in t-AUCB-treated WT versus WT mice at baseline and post-ischemia (p < 0.0001, Fig. 3B). As
a result, the ratio of 14,15-EET/DHET increased in t-AUCB-treated WT versus WT mice at
baseline (by 96%) and post-ischemia (by 173%; p ≤ 0.05, Fig. 3C). Our technique also detected
11,12-DHET, which decreased in t-AUCB-treated WT versus WT mice at baseline and postischemia (p < 0.001, Fig. 3D). There was no differences in levels of 14,15-EET, 14,15-DHET, or
11,12-DHET pre- and post-ischemia within each group.

Our LC–MS/MS detected 4 mid-chain HETEs (5-, 11-, 12-, and 15-HETE) in WT and t-AUCBtreated WT mouse heart perfusates. In WT mice, levels of 5-, 11-, 12-, and 15-HETE decreased
post-ischemia (after perfusion was reinstated) compared to baseline, but this was only significant
for 5-, 11-, and 15-HETE (p ≤ 0.05, Fig. 4A, B, and D). These mid-chain HETEs had a
decreasing trend post-ischemia compared to baseline in t-AUCB-treated WT mice, but this trend
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was not significant (p > 0.05, Fig. 4A-D). Treatment with t-AUCB decreased HETE levels in
WT mice, which was significant for 5-, 11-, and 15-HETE at baseline (p < 0.05, Fig. 4A, B, and
D) and 11-HETE post-ischemia (p < 0.05, Fig. 4B).

Linoleic acid (LA) epoxides (9,10- and 12,13-EpOME) levels had an increasing trend at baseline
and post-ischemia in t-AUCB-treated WT versus WT mice, but was not significant (p > 0.05,
Fig. 5A). The corresponding 9, 10- and 12, 13-DiHOME levels decreased at baseline and postischemia in t-AUCB-treated WT versus WT mice (p < 0.001, Fig. 5B). As a result, the
EpOME/DiHOME ratio increased in t-AUCB-treated WT compared to WT mice at baseline and
post-ischemia

(p

<

0.0001,

Fig.

5C).

The

measured

EpOMEs,

DiHOMEs,

and

EpOME/DiHOME ratio did not change post-ischemia versus baseline within the same group (p >
0.05, Fig. 5A-C).

Other LA hydroxylated metabolites, 9- and 13-HODE, increased in t-AUCB-treated WT versus
WT mice at baseline and post-ischemia (p < 0.05, Fig. 6); however, neither HODE level changed
post-ischemia versus baseline within the same group (p > 0.05, Fig. 6).

The levels of 6K-PG-F1, PG-F2, TxB2, PG-D2, and PG-E2 was also detected by our LC–
MS/MS. Treatment of WT mouse hearts with t-AUCB at baseline and post-ischemia decreased
6-keto-PG-F1(p < 0.05, Fig. 7A), PG-F2(p < 0.05, Fig. 7B), TxB2 (p < 0.05, Fig. 7C), PG-D2
(p < 0.05, Fig. 7D), and PG-E2 (p < 0.05, Fig. 7E). Compared to baseline WT levels, postischemia WT levels decreased for TxB2 and PG-D2, but were significant (p < 0.05) only for TxB2
(Fig. 7C).
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Effect of MS-PPOH (CYP epoxygenase inhibitor) on CRH Response in WT Mice
MS-PPOH attenuated CRH in WT mice (Fig. 8A). RV was decreased by 19% in MS-PPOHtreated WT versus WT mice (6.6 ± 0.4 and 5.3 ± 0.4 mL/g respectively, p ≤ 0.05, Fig. 8B).
Baseline CF was also decreased by 26% in MS-PPOH-treated WT versus WT mice (13.2 ± 0.4
and 9.7 ± 0.6 mL/g respectively, p ≤ 0.05, Fig. 8E). As a result, the debt volume (calculated as
the area under the CF curve during the 15 second ischemia) was decreased and, subsequently, the
R/D ratio was increased in MS-PPOH-treated WT compared to WT mice (1.9 ± 0.1 and 2.4 ± 0.2
respectively, p ≤ 0.05, Fig. 8C). PHF was slightly decreased in MS-PPOH-treated WT versus
WT mice (33.6 ± 0.7 and 32.4 ± 0.7 mL/min/g respectively, p ≤ 0.05, Fig. 1F). RD (Fig. 8D),
HR, and LVPD were not different between the two groups (p > 0.05).

Effect of T0070907 (PPARγ antagonist) on CRH response in WT Mice
Administering T0070907 to WT mouse hearts attenuated CRH. In T0070907-treated WT versus
WT mice, RV was decreased by 32% (from 6.6 ± 0.7 to 4.5 ± 0.6 mL/g, p < 0.05, Fig. 9A), RD
by 50% (from 2.1 ± 0.5 to 1.1 ± 0.2 min, p < 0.05, Fig. 9B), and baseline CF by 10% (from 16.3
± 0.7 to 15.1 ± 1.5 mL/min/g, p < 0.05, Fig. 9D). The R/D ratio decreased from 1.7 ± 0.3 to 1.2 ±
0.1, but was not significant (p > 0.05, Fig. 9C). LVDP, PHF, and HR were not different between
the two groups (p > 0.05, data not shown).

Effect of T0070907on t-AUCB–enhanced CRH in WT Mice
Pharmacologic inhibition of sEH by t-AUCB enhanced CRH in WT mice, as mentioned earlier
(Fig. 1). This same experiment was repeated with the PPARγ-antagonist T0070907 added to
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study its effect on t-AUCB-enhanced CRH. Infusion of t-AUCB increased RV in WT mice (from
6.0 ± 0.7 to 7.6 ± 0.5 mL/g, p < 0.05, Fig. 10A), R/D ratio (from 1.4 ± 0.1 to 1.9 ± 0.2, p < 0.05,
Fig. 10B), and RD (from 1.6 ± 0.2 to 3.1 ± 0.3, p < 0.05, Fig. 10C). t-AUCB–enhanced CRH
was attenuated by T0070907. RV in t-AUCB-treated WT mice was decreased (from 7.6 ± 0.5 to
4.3 ± 0.2 mL/g, p < 0.05, Fig. 10A), as was the R/D ratio (from 1.9 ± 0.2 to 1.1 ± 0.2, p < 0.05,
Fig. 10B) and RD (from 3.1 ± 0.3 to 1.6 ± 0.3, p > 0.05, Fig. 10C). Baseline CF, PHF, HR and
LVDP were not significantly changed among the 3 groups (WT, [WT + t-AUCB], and [WT + tAUCB + T0070907], data not shown).

Effect of rosiglitazone (PPARγ agonist) on CRH Response in WT Mice
Infusion of rosiglitazone enhanced CRH in WT mice. In rosiglitazone-treated WT versus WT
mice, RV increased by 33% (from 6.1 ± 0.3 to 8.1 ± 0.9 mL/g, p < 0.05, Fig. 11A), RD by 33%
(from 1.6 ± 0.1 to 2.1 ± 0.3 min, p < 0.05, Fig. 11B), R/D ratio by 31% (from 1.6 ± 0.1 to 1.9 ±
0.2, p < 0.05, Fig. 11C), and baseline CF from 15.2 ± 0.1 to 17.1 ± 0.7 mL/min/g (p < 0.05, Fig.
11D). PHF, LVDP and HR were not different between the two groups (p > 0.05, data not
shown). We summarized our observed results into a proposed schematic diagram (Fig. 12).
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Figures and Figure Legends
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Figure 2.1: Comparison of coronary reactive hyperemia (CRH) before (WT) and after (tAUCB-treated WT) infusion of t-AUCB.
(A) tracing depicting coronary flow (CF) changes at baseline (before CRH) and after CRH was
induced by 15-second no-flow ischemia in WT (continuous line) and WT + t-AUCB (dashed
line). Repayment volume (B), repayment duration (C), repayment/debt ratio (D), and peak
hyperemic flow (E) increased in t-AUCB-treated WT versus WT mice (p < 0.05). * p ≤ 0.05
versus WT. n = 8.
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Figure 2.2: Effect of sEH-inhibitor, t-AUCB, on coronary reactive hyperemia (CRH) in
sEH-null (sEH–/–) mice.
t-AUCB did not (p > 0.05) affect CRH in sEH–/– mice, as evident in the unchanged repayment
volume (A), repayment/debt ratio (B), and repayment duration (C) (p = 0.690). n = 6.
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Figure 2.3: LC–MS/MS analysis for 14, 15–EET, 14, 15–DHET, and 11,12–DHET levels in
WT and t-AUCB-treated WT mouse heart perfusates at baseline (pre-ischemia) and
directly after 15-second ischemia (post-ischemia).
(A) At baseline and post-ischemia levels of 14, 15–EET had an increasing trend in t-AUCBtreated WT versus WT mice, but this trend was not significant. (B) 14, 15–DHET levels
decreased at baseline and post-ischemia in t-AUCB-treated WT versus WT (p < 0.0001). (C) The
65

14, 15–EET/14, 15–DHET ratio increased (p < 0.05) in t-AUCB-treated WT versus WT mice at
baseline (by 96%) and post-ischemia (by 173%). (D) 11, 12–DHET levels decreased (p < 0.001)
at baseline and post-ischemia in t-AUCB-treated-WT versus WT mice. There was no difference
in 14,15-EET, 14,15-DHET, and 11,12-DHET levels pre- and post-ischemia within each group.
* p ≤ 0.05 versus baseline WT. # p≤0.05 versus post-ischemia WT. n = 8.
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Figure 2.4: LC–MS/MS analysis of 5-, 11-, 12- and 15-HETE levels in WT and t-AUCBtreated WT mouse heart perfusates at baseline (pre-ischemia) and post-ischemia.
In WT mice, 5-, 11-, 12- and 15-HETE levels decreased post-ischemia compared to baseline, but
this was only significant for 5-HETE (A), 11-HETE (B), and 15-HETE (D) (p < 0.05). The same
mid-chain HETEs had a decreasing trend post-ischemia compared to baseline in t-AUCB-treated
WT mice, but this was not significant (p > 0.05, A-D). Treatment with t-AUCB decreased HETE
levels in WT mice, which was significant for 5-HETE (A), 11-HETE (B) and 15-HETE (D)
levels at baseline (p < 0.05), and in 11-HETE levels post-ischemia (p < 0.05, B). * p ≤ 0.05
versus baseline WT. # p≤0.05 versus post-ischemia WT. n = 8.
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levels

and

the

EpOME/DiHOME ratio in WT and t-AUCB-treated-WT mouse heart perfusates at
baseline (pre-ischemia) and post-ischemia.
(A) 9,10- and 12,13-EpOME levels had an increasing trend at baseline and post-ischemia in tAUCB-treated-WT versus WT mice, but this was not significant (p > 0.05). Neither EpOME was
significantly changed post-ischemia compared to baseline in both groups. (B) 9,10- and 12,13DiHOME levels decreased at baseline and post-ischemia in t-AUCB-treated-WT versus WT
mice (p < 0.001). (C) The EpOME/DiHOME ratio increased in t-AUCB-treated versus WT mice
at baseline and post-ischemia (p < 0.0001). The measured EpOME and DiHOME levels and
EpOME/DiHOME ratio did not change post ischemia versus baseline within the same group (p >
0.05, A-C). * p ≤ 0.05 versus baseline WT. # p ≤ 0.05 versus post-ischemia WT. n = 8.
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Figure 2.6: LC–MS/MS analysis of HODEs in WT and t-AUCB-treated WT mouse heart
perfusates at baseline (pre-ischemia) and post-ischemia.
9- and 13-HODE increased in t-AUCB-treated WT versus WT mice at baseline and postischemia (p < 0.05). Neither HODE changed post-ischemia versus baseline within the same
group (p > 0.05). * p ≤ 0.05 versus baseline WT. # p ≤ 0.05 versus post-ischemia WT. n = 8.
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Figure 2.7: LC–MS/MS analysis of 6-keto-PG-F1, PG-F2, thromboxane B2, PG-D2, and
PG-E2 in WT and t-AUCB-treated WT mouse heart perfusates at baseline (pre-ischemia)
and post-ischemia.
Infusion of t-AUCB decreased 6-keto-PG-F1 (A), PG-F2, (B), thromboxane B2 (C), PG-D2 (D),
and PG-E2 (E), at baseline and post-ischemia (p≤0.05). Compared to baseline WT, post-ischemia
WT levels were decreased for thromboxane B2, and PG-D2, but were significant (p < 0.05) only
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for thromboxane B2 (C). * p ≤ 0.05 versus baseline WT. # p ≤ 0.05 versus post-ischemia WT. n =
8.
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Figure 2.8: Effect of CYP-epoxygenase inhibitor (MS-PPOH, 1 M) on coronary reactive
hyperemia (CRH) in wild type (WT) mice.
Each WT isolated mouse heart was used as its own control. (A) tracing depicting coronary flow
changes at baseline (before CRH) and after CRH was induced by 15-second no-flow ischemia in
WT (continuous line) and MS-PPOH-treated WT (dashed line) mice. Repayment volume (B),
baseline CF (E), PHF (F), and LVDP (G) decreased (p < 0.05) in MS-PPOH-treated WT versus
WT mice. Repayment/debt ratio (C) increased (p < 0.05), whereas repayment duration (D) did
not change (p > 0.05) after in MS-PPOH-treated WT versus WT mice. * p ≤ 0.05 versus WT. n =
8.
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Figure 2.9: Effect of T0070907, PPAR-antagonist (10 M) on coronary reactive hyperemia
(CRH) in wild type (WT) mice.
Each WT isolated mouse heart was used as its own control. Infusion of T0070907 into WT mice
hearts attenuated CRH. (A) Repayment volume decreased (p < 0.05), as did RD (B) (p < 0.05)
and baseline CF (D) (p < 0.05). Repayment/debt ratio (C) had a decreasing trend, but was not
significant (p > 0.05). * p≤0.05 versus WT. n = 8.
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Figure 2.10: Effect of T0070907, PPAR-antagonist (10 M) on t-AUCB-enhanced CRH in
WT in wild type (WT) mice.
Each WT isolated mouse heart was used as its own control. Inhibition of sEH by t-AUCB
enhanced CRH in WT mice. Infusion of t-AUCB (10 M) increased repayment volume (RV) (p
< 0.05, A), repayment/debt ratio (p < 0.05, B), and repayment duration (RD) in WT mice (p <
0.05, C). The t-AUCB-enhanced CRH was attenuated by T0070907. T0070907 decreased RV
(A), R/D ratio (B), and RD (C) in t-AUCB-treated-WT mice (p < 0.05). * p≤0.05 versus WT. n =
6.
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Figure 2.12: A schematic diagram comparing the oxylipin changes observed in response to
a brief ischemia and their possible impact on coronary reactive hyperemia (CRH) between
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Discussion
Pharmacologic inhibition of sEH in WT mice enhanced CRH in an isolated heart model after
brief ischemia. sEH inhibition was also associated with changes in various oxylipin profiles. The
relationship among inhibition of CYP epoxygenases, inhibition of sEH, oxylipins, and PPARγ in
the modulation of CRH in isolated mouse hearts is not known. Therefore, this study was
designed to investigate the role of sEH, oxylipins, and PPARγ in the modulation of CRH using
isolated WT mouse hearts. Our data demonstrated that: 1) Inhibition of sEH by t-AUCB
enhanced CRH; 2) Treatment with t-AUCB significantly changed oxylipin profiles, including an
increased EET/DHET ratio, increased EpOME/DiHOME ratio, increased HODEs, decreased
mid-chain HETEs, and decreased prostanoids; 3) Inhibition of CYP epoxygenases (by MSPPOH) attenuated CRH; 4) The PPARγ antagonist T0070907 decreased CRH and t-AUCB–
enhanced CRH, and 5) the PPARγ agonist rosiglitazone increased CRH.

Inhibition of sEH by t-AUCB significantly enhanced CRH after brief ischemia compared to
non-treated WT mice. The association between compromised CRH and some cardiovascular
pathologies (6, 30, 36) confirms the significance of CRH. Further, the t-AUCB-enhanced CRH
was accompanied by a 1.0- (at baseline) to 1.7- (post-ischemia) fold increase in the 14,15EET/DHET ratio, primarily driven by a decrease in 14,15-DHET. Similarly, another dihdroxyEET metabolite (11,12-DHET) decreased in t-AUCB–treated mouse hearts, further confirming
the efficacy of the sEH-inhibitor, t-AUCB. The specificity of t-AUCB as a sEH inhibitor was
tested using sEH knockout (sEH–/–) mice, where no difference in CRH between the t-AUCBtreated sEH–/– versus non-treated sEH–/– mice was observed. The rapid hydration of EETs
(24) may explain the challenge of detecting them. We were able to detect 14,15 -
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EET and two diols (11,12- and 14,15-DHETs) in heart perfusate samples. As
mentioned earlier, EETs are formed by the epoxidation of arachidonic acid (AA) by CYP
epoxygenases and possess well-established beneficial cardiovascular effects (19, 53, 59, 85,
102), including protection against ischemia/reperfusion injury (77), and vasodilation in many
vascular beds such as the intestines (71), kidney preglomerular vasculature (33), and brain (23).
Inhibition of sEH, the main catabolic enzyme of EETs, has been widely used to increase the
level of EETs and to investigate their effects (45). Acute inhibition of sEH, through injection of
a sEH inhibitor, lowered blood pressure in spontaneously hypertensive rats (SHR) (101),
whereas chronic inhibition of sEH lowered angiotensin-II–induced hypertension (34). Besides
lowering blood pressure, sEH inhibition ameliorated renal damage in angiotensin-dependent,
salt-sensitive hypertension rats (35). In the current study, the brief ischemia had no effect on
EET or DHET levels. This could be due to the short duration of ischemia (15 seconds). In
contrast, DHETs (EETs metabolites) were elevated in the mouse heart perfusate in response to
longer (20-min) ischemia (17). Another interesting finding in the current study was that no
significant difference was found in CRH between male and female mice in either t-AUCB–
treated or non–treated groups. Based on our data, the enhancement of CRH associated with sEH
inhibition in WT mice may be partially due to an increase in the EET/DHET ratio.
Mid-chain (5-, 11-, 12- and 15-) HETE levels decreased in response to ischemia and to tAUCB treatment at baseline and post-ischemia. Mid-chain HETEs are produced through allylic
oxidation of AA by lipoxygenase (LOX) (39). They were shown to have chemotaxis effects,
change vascular tone, and induce the production of vascular endothelial growth factors (29, 56,
86, 93). Also, the increased formation of mid-chain HETEs was involved in cardiovascular
dysfunction (13, 68, 87, 97). Unlike the vasodilatory effect of EETs in the kidneys (33), 12-
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HETE caused vasoconstriction in small renal arteries (48). Also, the generation of mid-chain
HETEs is increased in essential hypertension (16) suggesting that they could be involved in its
pathogenesis. These reports point to opposite effects of EETs and HETEs in vascular biology.
Maayah et al. reported that mid-chain HETEs blocked the synthesis of EETs and increased their
conversion to DHETs in RL-14 cells (49). Moreover, although sEH is not directly involved in the
generation or breakdown of mid-chain HETEs, sEH was found to be essential for mid-chain
HETE–mediated induction of cellular hypertrophy (49). Therefore, not only do EETs and midchain HETEs have opposite effects, they seem to affect the level of each other. In contrast to our
findings, Li et al. reported that the plasma levels of 5-, 11-, 12-, and 15-HETE were not changed
by sEH-inhibition in WT mice (45). However, their results were based on plasma samples,
whereas ours were based on isolated heart perfusate samples and demonstrated significant
decrease in the level of the same HETEs in response to sEH inhibition. Based on these results, the
decrease in mid-chain HETEs in both t-AUCB-treated and non-treated mice in response to
ischemia suggests that these metabolites are down regulated in response to ischemic episodes.
This is an interesting finding because HETEs were the only oxylipins analyzed in this paper
whose levels were affected by the brief ischemia. Also, the further decrease of these HETEs by tAUCB–treatment may have played a role in the enhanced CRH observed in t-AUCB–treated
hearts.
Linoleic acid (LA) epoxidation metabolites, such as 9,10-, and 12,13-EpOMEs, and their
corresponding sEH-metabolized DiHOMEs were detected in the heart perfusate samples. As
expected, inhibition of sEH by t-AUCB was further confirmed by an increased
EpOME/DiHOME ratio. This resulted from increased 9,10-,12,13-EpOMEs (albeit not
statistically significant), and decreased 9,10-, 12,13-DiHOMEs in t-AUCB–treated versus non-
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treated mice. The physiological significance of EpOMEs and DiHOMEs remains poorly
understood, and the evidence is somewhat contradictory, with a few studies suggesting toxic
effects, while others indicating beneficial effects of these bioactive metabolites. EpOMEs and
DiHOMEs were reported to increase oxidative stress in vascular endothelial cells (96);
DiHOMEs were toxic to renal proximal tubular cells (54); and intravenously injected 9,10EpOME had cardiodepressive effects in dogs (90). The main caveat of these studies, which
reported that EpOMEs and DiHOMEs have toxic effects, is that very high concentrations (100 –
500 M) were used (39). Contrary to these reports, lower, more physiological concentrations of
EpOMEs and DiHOMEs did not have toxic effects and rather had beneficial effects (52).
Mitchell et al reported that LA and its oxidative metabolites (EpOMEs and DiHOMEs) did not
have toxic effects during acute exposure in Langendorff-perfused rat hearts (52). Pretreatment
with 12,13-EpOME protected primary cultures of rabbit renal proximal tubular cells against
hypoxia/reoxygenation injury (65). Also, increased EpOME/DiHOME ratio, induced by sEH
inhibition using AUDA, improved renal recovery in response to ischemia/reperfusion injury in
C57BL/6 mice (44). Based on these findings and on the described biologic role of LA epoxides,
the increase in EpOME/DiHOME ratio in t-AUCB–treated mouse heart perfusates may have
contributed to enhancing CRH.
Linoleic acid (LA) is also metabolized through hydroxylation by CYP epoxygenases to
form hydroxyl-LA metabolites known as hydroxyoctadecadienoic acids (HODEs) (39). The
detected two HODE isomers, 9-, and 13-HODE, were increased in t-AUCB-treated WT. Like
EpOMEs, the physiologic functions of HODEs are still being investigated (39). 13-HODE is
suggested to have an anti-inflammatory role in inflammatory diseases through its effect as a
PPARγ-agonist (2, 4, 18, 21, 88). Also, 13-HODE, through increasing prostacyclin (PGI2)
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biosynthesis, was involved in splenic and coronary artery relaxation in smooth muscle cells in
Mongrel dogs (15). 9-HODE, unlike 13-HODE, was described as pro-inflammatory in an
experimental wound-healing model in rats (26, 66). In contrast to 13-HODE, which can be
produced from LA by the action of 12/15-LOX, 9-HODE production by LOX has not been
reported in humans; rather, mouse 8-LOX metabolizes LA to 9-HODE (66). In contrast to our
data, Luria et al. reported no change in 9– and 13–HODE in sEH–/– compared to sEH+/+ (47).
This discrepancy may be explained by the difference in the source of the metabolites: we used
heart perfusate samples, whereas Luria et al (47) used urinary samples. Also, the reported
metabolic and functional effects of sEH–/– (genetic deletion of sEH) and pharmacologic
inhibition of sEH are not necessarily the same (45). Therefore, and based on our results, the
increase in 13-HODE in t-AUCB–treated mouse heart perfusates might have played a role in
enhancing CRH, whereas the role of 9-HODE is not yet known based on its, thus far, described
biologic functions.
Treatment of WT mice hearts with t-AUCB significantly decreased prostanoid levels,
including PGs and TxB2. PG-G2 and PG-H2, AA metabolites formed by COX isoforms (1 and 2),
are converted to the 4 main bioactive PGs (PG-D2, PG-E2, PG-I2, PG-F2) and thromboxanes
(TxA2 and TxB2) (74, 92). Most PGs have pro-inflammatory effects. For example, PG-E2
augments arterial dilation and increases microvascular permeability (92). However, PG-E2 was
found to have an anti-inflammatory role as well by up-regulating cAMP and inducing secretion of
the anti-inflammatory IL-10 (78). Similarly, PG-D2 attenuated inflammation in experimental
models of pleuritis and colitis (92). 6-keto-PG-F1, the non-active hydrolysis product of
prostacyclin (PG-I2), and TxB2, the inactive degradation product of TxA2 (92), were also
decreased by t-AUCB. PG-F2 is elevated in patients with chronic inflammatory diseases (92). In
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support of our findings, sEH-inhibition by AUDA-BE reversed lipopolysaccharide (LPS)-induced
increase in PG-D2, PG-E2, 6-keto-PG-F1, and TxB2 (76). Also, sEH-inhibition by AUDA-BE,
through increasing the concentrations of EETs, inhibited NF-B translocation (75). Combination
of sEH-inhibition by AUDA-BE and COX-inhibition had an additive effect and further decreased
PG-D2 and PG-E2 (75). Therefore, the associated decrease in the measured PGs could be
attributed to sEH-inhibition by t-AUCB. However, the impact of these changes on the t-AUCB–
enhanced CRH is not yet clear.

As mentioned earlier, EETs are generated from AA by cytochrome P450 (CYP)
epoxygenase enzymes, primarily CYP2C and CYP2J. We targeted the CYP epoxygenase-EET
pathway using pharmacologic inhibition of CYP-epoxygenases to further support our findings of
the involvement of CYP-epoxygenases in modulating CRH. sEH-inhibition increases the level of
EETs by blocking their breakdown; we investigated the effect of blocking the synthesis of EETs
on CRH using a CYP epoxygenases-inhibitor. Evidently, inhibiting CYP epoxygenases would
negatively impact EET synthesis and, therefore, their effects. P450 enzymes are highest in
coronary arteries and in small arterioles (20). MS-PPOH was used as an EET-synthesis inhibitor
that blocked the role of EETs as mediators of insulin-mediated augmentation of skeletal muscle
perfusion (82). Our data indicate that MS-PPOH significantly decreased CRH after a brief
ischemia. These findings suggest that inhibition of CYP epoxygenases by MS-PPOH decreased
CRH possibly due to inhibition of EETs synthesis. Further studies to investigate the impact of
MS-PPOH on oxylipin profiles are needed to understand the metabolic changes associated with
the inhibition of CYP epoxygenases.
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This study also showed that CRH was decreased by T0070907, a PPARγ-antagonist,
whereas rosiglitazone, a PPARγ-agonist, increased CRH. Moreover, T0070907 attenuated tAUCB–enhanced CRH in WT mouse hearts. Studies indicated that EET effects could be
mediated by PPARγ receptors (8, 14, 46, 70). Liu et al. suggested that selective sEH inhibition
potentiates the anti-inflammatory effect in endothelial cells by increasing the retention of EETs
so that PPAR activation is prolonged (46). Our results suggest that PPARγ receptors are
involved in modulating CRH. Also, the attenuated t-AUCB–enhanced CRH in WT mice (by
T0070907) suggests that PPARγ may mediate CRH downstream of CYP epoxygenases-EET
pathway.

In summary, the findings of this study suggest that the CYP epoxygenases-EET pathway
may have a role in mediating CRH possibly through PPARγ activation, as noted by sEHinhibition, which enhanced CRH, and CYP epoxygenases-inhibition, which decreased CRH.
Also, sEH-inhibition is accompanied by changes in AA oxylipins (increased EET/DHET ratio,
decreased mid-chain HETEs, and decreased prostanoids) and LA oxylipins (increased
EpOME/DiHOME ratio, and increased HODEs), which might have collectively accounted for
the observed enhancement of CRH. Therefore, we conclude that sEH-inhibition enhances,
whereas CYP epoxygenases-inhibition attenuates CRH, PPARγ activation mediates CRH
downstream of the CYP epoxygenases-EET pathway, and the changes in oxylipin profiles
associated with sEH-inhibition collectively account for the enhanced CRH.
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CHAPTER THREE

DISCUSSION, SUMMARY and CONCLUSIONS

Discussion
Targeting sEH, through pharmacologic inhibition or genetic deletion, enhanced CRH in an
isolated heart model after brief ischemia. sEH disruption was also associated with changes in
various oxylipin profiles. We investigated the role of sEH, oxylipins, and PPARγ in the
modulation of CRH using isolated mouse hearts. Our data demonstrated that: 1) Targeting sEH,
through pharmacologic inhibition or genetic deletion, enhanced CRH; 2) Disruption of sEH
significantly changed oxylipin profiles, including an increased EET/DHET ratio, increased
EpOME/DiHOME ratio, increased HODEs, decreased mid-chain HETEs, and decreased
prostanoids; 3) Inhibition of CYP epoxygenases pathway attenuated CRH; and 4) The PPARγ
receptors are involved in CRH as evident by the effect of PPARγ-antagonist and PPARγ-gonist
used.

Disruption of sEH by pharmacologic inhibition (t-AUCB) or genetic deletion (sEH–/–)
enhanced CRH after brief ischemia compared to control mice. CRH may be viewed as a
protective mechanism, and is attenuated in pathologic conditions. The association between
compromised CRH and some cardiovascular pathologies, such as cardiac hypertrophy (36),
metabolic syndrome (6), unstable angina, myocardial infarction, congestive heart failure and
cardiac death (30) confirms the significance of CRH. Further, the disrupting CRH was
accompanied by significant increase in the measured EET and reduction in the corresponding
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DHETs. The rapid hydration of EETs (24) may explain the challenge of detecting
them. EETs are formed by the epoxidation of arachidonic acid (AA) by CYP epoxygenases and
possess well-established beneficial cardiovascular effects (19, 53, 59, 85, 102). Deletion or
inhibition of sEH, the main catabolic enzyme of EETs, has been widely used to increase the
level of EETs and to investigate their effects (45). Acute inhibition of sEH, through injection of
a sEH inhibitor, lowered blood pressure in spontaneously hypertensive rats (SHR) (101),
whereas chronic inhibition of sEH lowered angiotensin-II–induced hypertension (34). Besides
lowering blood pressure, sEH inhibition ameliorated renal damage in angiotensin-dependent,
salt-sensitive hypertension rats (35). Also, deletion of sEH gene increases endogenous EETs
by decreasing the metabolic conversion of EETs into DHETs. The observed CRH increase in
mice due to sEH disruption through pharmacology or gene deletion was associated with an
increase in 14,15-EET/14,15-DHET ratio without changing basic cardiac functions.
The brief ischemia had no effect on EET or DHET levels, which could be due to the short
duration of ischemia (15 seconds). In contrast, DHETs (EETs metabolites) were elevated in the
mouse heart perfusate in response to longer (20-min) ischemia (17).
Mid-chain (5-, 11-, 12- and 15-) HETE levels decreased in response to ischemia and to
sEH-inhibition t-AUCB treatment, but not in sEH–/–. Mid-chain HETEs are produced through
allylic oxidation of AA by lipoxygenase (LOX) (39). Increased formation of these mid-chain
HETEs is involved in cardiovascular dysfunction through endothelial cells, smooth muscle cells,
and monocytes (13, 68, 87, 97). They were shown to have chemotaxis effects, change vascular
tone, and induce the production of vascular endothelial growth factors (29, 56, 86, 93). Unlike the
vasodilatory effect of EETs in the kidneys (33), 12-HETE caused vasoconstriction in small renal
arteries (48). Also, the generation of mid-chain HETEs is increased in essential hypertension (16)
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suggesting that they could be involved in its pathogenesis. These reports point to opposite effects
of EETs and HETEs in vascular biology. Maayah et al. reported that mid-chain HETEs blocked
the synthesis of EETs and increased their conversion to DHETs in RL-14 cells (49). Moreover,
although sEH is not directly involved in the generation or breakdown of mid-chain HETEs, sEH
was found to be essential for mid-chain HETE–mediated induction of cellular hypertrophy (49).
Therefore, not only do EETs and mid-chain HETEs have opposite effects, they seem to affect the
level of each other. In contrast to our findings, Li et al. reported that the plasma levels of 5-, 11-,
12-, and 15-HETE were not changed by sEH-inhibition in WT mice (45). However, their results
were based on plasma samples, whereas ours were based on isolated heart perfusate samples, and
demonstrated significant decrease in the level of 5-, 11-, 12-, and 15-HETEs in response to sEH
inhibition. Also, Li et al. reported the plasma levels of 5-, 9-, 11-, and 15-HETEs were elevated in
sEH–/– compared to sEH+/+ mice (45). Again, this discrepancy could be explained by the different
source of the samples; ours were from the isolated heart perfusate, whereas theirs were from the
plasma (45). Based on our findings, the decrease in mid-chain HETEs in response to ischemia
suggests that these metabolites are down regulated in response to ischemic episodes. This is an
interesting finding because, out of all oxylipins measured, HETEs were the only oxylipins whose
levels were affected by the brief ischemia.
Linoleic acid (LA) epoxidation metabolites, such as 9,10-, and 12,13-EpOMEs, and their
corresponding sEH-metabolized DiHOMEs were detected in the heart perfusate samples. As
expected, targeting sEH through inhibition (by t-AUCB) or deletion (sEH–/–) increased
EpOME/DiHOME ratio. This resulted from increased 9,10-,12,13-EpOMEs, and decreased 9,10, 12,13-DiHOMEs. The physiological significance of EpOMEs and DiHOMEs remains poorly
understood, and the evidence is somewhat contradictory, with a few studies suggesting toxic
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effects, while others indicating beneficial effects of these bioactive metabolites. EpOMEs and
DiHOMEs were reported to increase oxidative stress in vascular endothelial cells (96);
DiHOMEs were toxic to renal proximal tubular cells (54); and intravenously injected 9,10EpOME had cardiodepressive effects in dogs (90). The main caveat of these studies, which
reported that EpOMEs and DiHOMEs had toxic effects, is that very high concentrations (100 –
500 M) were used (39). Contrary to these reports, lower, more physiological concentrations of
EpOMEs and DiHOMEs did not have toxic effects and rather had beneficial effects (52).
Mitchell et al reported that LA and its oxidative metabolites (EpOMEs and DiHOMEs) did not
have toxic effects during acute exposure in Langendorff-perfused rat hearts (52). Pretreatment
with 12,13-EpOME protected primary cultures of rabbit renal proximal tubular cells against
hypoxia/reoxygenation injury (65). Also, increased EpOME/DiHOME ratio, induced by sEH
inhibition using AUDA, improved renal recovery in response to ischemia/reperfusion injury in
C57BL/6 mice (44). Based on these findings and on the described biologic role of LA epoxides,
the increase in EpOME/DiHOME ratio may have contributed to enhancing CRH.

Linoleic acid (LA) is also metabolized through hydroxylation by CYP epoxygenases to
form hydroxyl-LA metabolites known as hydroxyoctadecadienoic acids (HODEs) (39). The
detected 13-HODE was increased in t-AUCB-treated and sEH–/– mice versus corresponding
controls. However, 9-HODE increased in t-AUCB-treated mice, but didn’t change in sEH–/– vs.
sEH+/+ mice. 9-HODE is considered pro-inflammatory, activating G protein coupled receptor and
JNK (26, 66). Similar to EpOMEs, the physiologic function of HODEs is still being investigated
(39). 13-HODE is suggested to have an anti-inflammatory role in inflammatory diseases through
its effect as a PPARγ-agonist (2, 4, 18, 21, 88). Also, 13-HODE, through increasing prostacyclin
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(PGI2) biosynthesis, was involved in splenic and coronary artery relaxation in smooth muscle
cells in Mongrel dogs (15). 9-HODE, unlike 13-HODE, was described as pro-inflammatory in an
experimental wound-healing model in rats (26, 66). In contrast to our data, Luria et al. reported
no change in 9– and 13–HODE in sEH–/– compared to sEH+/+ (47). This discrepancy may be
explained by the difference in the source of the metabolites: we used heart perfusate samples,
whereas Luria et al (47) used urinary samples. Also, the reported metabolic and functional
effects of sEH–/– (genetic deletion of sEH) and pharmacologic inhibition of sEH are not
necessarily the same (45). Therefore, based on our results, the increase in 13-HODE in sEHdisrupted heart perfusates might have played a role in enhancing CRH, whereas the role of 9HODE is not yet known based on its described biologic functions.

sEH inhibition with t-AUCB decreased prostanoid levels, including PGs and TxB2. PG-G2
and PG-H2, AA metabolites formed by COX isoforms (1 and 2), are converted to the 4 main
bioactive PGs (PG-D2, PG-E2, PG-I2, PG-F2) and thromboxanes (TxA2 and TxB2) (74, 92). Most
PGs have pro-inflammatory effects. For example, PG-E2 augments arterial dilation and increases
microvascular permeability (92). However, PG-E2 was found to have an anti-inflammatory role
as well by up-regulating cAMP and inducing secretion of the anti-inflammatory IL-10 (78).
Similarly, PG-D2 attenuated inflammation in experimental models of pleuritis and colitis (92). 6keto-PG-F1, the non-active hydrolysis product of prostacyclin (PG-I2), and TxB2, the inactive
degradation product of TxA2 (92), were also decreased by t-AUCB. PG-F2 is elevated in patients
with chronic inflammatory diseases (92). In support of our findings, sEH-inhibition by AUDABE reversed lipopolysaccharide (LPS)-induced increase in PG-D2, PG-E2, 6-keto-PG-F1, and
TxB2 (76). Also, sEH-inhibition by AUDA-BE, through increasing the concentrations of EETs,
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inhibited NF-B translocation (75). Combination of sEH-inhibition by AUDA-BE and COXinhibition had an additive effect and further decreased PG-D2 and PG-E2 (75). Therefore, the
associated decrease in the measured PGs could be attributed to sEH-inhibition by t-AUCB.
However, the impact of these changes on the t-AUCB–enhanced CRH is not yet clear.
As mentioned earlier, EETs are generated from AA by cytochrome P450 (CYP)
epoxygenase enzymes, primarily CYP2C and CYP2J. The CYP epoxygenase-EET pathway was
targeted using pharmacologic inhibition of CYP-epoxygenases to further support our findings of
the involvement of CYP-epoxygenases in modulating CRH. sEH-inhibition increases the level of
EETs by blocking their breakdown; we investigated the effect of blocking the synthesis of EETs
on CRH using a CYP epoxygenases-inhibitor. Evidently, inhibiting CYP epoxygenases would
negatively impact EET synthesis and, therefore, their effects. CYP450 enzymes are highest in
coronary arteries and in small arterioles (20). MS-PPOH was used as an EET-synthesis inhibitor
that blocked the role of EETs as mediators of insulin-mediated augmentation of skeletal muscle
perfusion (82). Our data indicate that MS-PPOH significantly decreased CRH after a brief
ischemia. These findings suggest that inhibition of CYP epoxygenases by MS-PPOH decreased
CRH possibly due to inhibition of EETs synthesis. Further studies to investigate the impact of
MS-PPOH on oxylipin profiles are needed to understand the metabolic changes associated with
the inhibition of CYP epoxygenases.

Also, we investigated the relationship between CRH and PPARγ. Our data showed that
CRH was attenuated in sEH–/–, WT (sEH+/+), and t-AUCB–treated WT mouse hearts by
T0070907 (PPARγ-antagonist), but enhanced by rosiglitazone (PPARγ-agonist). These results
from PPARγ-antagonist and PPARγ-agonist experiments suggest that PPARγ receptors are
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involved in modulating CRH. Interestingly, studies indicated that EET effects could be
mediated by PPARγ receptors (8, 14, 46, 70). Our lab reported that sEH–/– mouse aorta had
increased expression of PPARγ protein and enhanced vascular relaxation compared to sEH+/+
mice (59). Liu et al. suggested that selective sEH inhibition potentiated the anti-inflammatory
effect in endothelial cells, presumably by increasing the retention of EETs, which would
activate PPAR (46). These studies indicate that EETs’ effects could be mediated by
PPARγ receptors. Also, the attenuated t-AUCB–enhanced CRH in WT mice (by T0070907)
suggests that PPARγ may mediate CRH downstream of CYP epoxygenases-EET pathway.
Infusion of L-NAME, a non-selective NO synthase inhibitor, decreased CRH in both
sEH+/+ and sEH–/– mice. These data suggest that the presence or absence of sEH does not have
any specific effect on L-NAME-induced attenuation of CRH response in both sEH+/+ and sEH–/–
mice. Similarly, Zhang et al. described that the inhibition of the activity of sEH enzyme
ameliorates endothelial dysfunction in the db/db mice, which is NO-independent, but dependent
on cyp450-epoxygenase-derived metabolites (EETs) (103). Our studies have shown that vascular
relaxation through A2AAR was independent of NO and cyclooxygenase pathways (57, 58,
60). Also, others (17, 39, 45) reported that sEH–/– mice were associated with elevated EETs
levels compared to sEH+/+ mice, and these EETs exerted cardioprotective effects against
ischemia/reperfusion injury (77). Therefore, the enhanced CRH in sEH–/– compared to sEH+/+
mice seems to be independent of the NO pathway, but dependent on the changes associated with
sEH-deletion. Although cyclooxygenase (COX) pathway was found to be involved in myocardial
reactive hyperemia in dogs, and a cross-talk between COX and nitric oxide pathways in dog
coronary vessels was suggested (72), a later publication by Hellmann et al. (27) suggested that
COX-metabolites, prostanoids, were not involved in reactive hyperemia in human skin.
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Accordingly, the role of prostanoids in mouse CRH was not investigated in our study, and
therefore, cannot be ruled out.

Summary and Conclusions:
Ischemia continues to pose significant health risks to people in both developed and
developing countries. The heart is mainly affected in ischemic heart disease (IHD), which has
been a leading cause of morbidity and mortality of long-standing industrialized countries, and in
countries with emerging economies (7). Consequences of ischemia on the heart range from
functional and structural damage to infarction and death. Physiologically, reperfusion after a
period of ischemia is accompanied by increased nourishment in what seems to be an attempt to
speed up recovery and to decrease the potential ischemia-induced damage. This increased
nourishment is known as coronary reactive hyperemia (CRH). Extensive research has been
dedicated to understanding the mechanisms and mediators of CRH. The association between
compromised CRH and some cardiovascular pathologies (6, 30, 36) confirms the significance of
CRH.
The confirmed beneficial effects of EETs, as shown in animal and human epidemiological
studies, such as cardioprotection against in ischemia / reperfusion injury (77), and vasodilation
(23, 33, 71) were the basis for our project. sEH is a key element in the biologic roles of EETs. It
has been targeted, through deletion or inhibition, to study the effects of EETs. However, studies
have also revealed that when sEH was targeted, other oxylipins were also affected. Oxylipins
have numerous biologic effects which are still to be uncovered.
Our findings demonstrate that targeting sEH, through pharmacologic inhibition or genetic
deletion, is associated with enhanced CRH, and with significant changes in arachidonic acid-

89

derived metabolites (EETs, prostanoids, and HETEs), and linoleic acid-derived metabolites
(EpOMEs, DiHOMEs, and HODEs). The enhanced CRH associated with disruption of sEH
could be through increased EET/DHET ratio, increased 13-HODE, and increased
EpOMEs/DiHOMEs ratio. Also, PPARγ activation mediates CRH downstream of the CYP
epoxygenases-EET pathway. Therefore, targeting sEH through pharmacology could be a
feasible option for clinical implementation in cardiovascular diseases in which the hyperemic
response is blunted or compromised.
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FUTURE DIRECTIONS

This research opens new prospects for combining functional and biochemical data in trying to
better understand the impact of ischemia on cardiac function and the effect of some lipid
mediators on modulating that response. It certainly contributes to our understanding of the
complex changes in many of the oxylipins in response to pharmacologic intervention or genetic
changes; however, it does create more questions regarding the exact role each of the measured
oxylipins play in the cardiac response to ischemic insults. More studies need to be done to assess
the effect of these different oxylpins on CRH through the use of agonists or antagonists. Luckily,
genetic models, which provide specific focus on enzymes involved in the formation or
breakdown of EETs. Such models include endothelial over-expression of CYP2J2 (Tie2-CYP2J2
Tr.) and endothelial over-expression sEH (Tie2-sEH Tr.). Future studies to investigate coronary
reactive hyperemia in these models compared to wild type need to be performed. Additionally,
oxylipins profiling in these models (Tie2-CYP2J2 Tr. and Tie2-sEH Tr.) will also improve our
understanding of how oxylipins change and what role they might play when different enzymes
are affected under ischemic conditions.
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2014 – 2016: ISM Sunday school Principal: after volunteering as a teacher for a semester, I was
elected principal for this 108-student Sunday school. I managed school curricula,
recruiting teachers, student s evaluation, and furniture and disposables supplies.
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2014:

Habitat for Humanity – Morgantown: volunteered to help in a number of
humanitarian projects inside Morgantown, such as building houses for people
who suffered homelessness due to natural disasters.
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